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ABSTRACT 
 
Chronic kidney disease is a progressive inflammatory disorder affecting approximately 
15% of US adults, and the prevalence is increasing rapidly. Advanced chronic kidney disease 
requiring hemodialysis is associated with multiple co-morbid conditions that greatly reduce 
physical function and quality of life, including muscle wasting, bone disorders, and 
cardiovascular disease.  Protein-energy malnutrition is especially common for reasons including 
poor nutrient intake, amino acid losses during dialysis, and elevated intradialytic catabolism; 
these factors promote loss of lean mass and declines in physical function.  Low physical function 
and adverse changes in body composition accelerate development of other co-morbid conditions, 
highlighting the cycle of disease and disability characteristic of this population. 
 Numerous pharmacological therapies are commonly used in an effort to reduce the 
incidence or severity of chronic kidney disease co-morbidities, but these treatments are 
associated with high costs and significant side effects.  Furthermore, the complexity of chronic 
kidney disease suggests multiple therapeutic approaches may be beneficial in this population.  
Intradialytic protein supplementation and exercise training during dialysis are two lifestyle 
interventions that have been suggested as potential methods to mitigate the cycle of disease and 
disability.  Studies have shown that both parenteral and oral intradialytic supplementation 
improve protein homeostasis, increase serum albumin and prealbumin levels, and have anabolic 
effects on skeletal muscle.  However, the effect of intradialytic protein on functional disease 
outcomes in this population is not known.  Similarly, numerous studies have demonstrated that 
intradialytic exercise training has beneficial effects on physical function and quality of life, but 
surprisingly few studies have examined its effect on other clinical outcomes, particularly 
cardiovascular disease.  
 The goal of this research was to examine the relationships between the comorbid 
conditions associated with advanced chronic kidney disease, and determine the efficacy of 
intradialytic protein supplementation and exercise training as therapeutic approaches.  This goal 
was accomplished through a series of studies both in animal models and also in clinical 
populations.  In a mouse model of renal insufficiency, a combination of soy protein and 
exercising improved bone microarchitecture and a main effect of soy protein consumption was 
observed for improvements plasma urea as an indicator of renal function; results from this study 
an others prompted consideration of these effects in a clinical population.
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In a cross-sectional analysis of sixty hemodialysis patients, we found multiple aspects of 
chronic kidney disease to be interrelated, supporting the idea of the cycle of disease and 
disability characteristic of these patients.  This study was notable for its comprehensive inclusion 
of functional outcome variables associated with hemodialysis treatment in an effort to 
characterize relationships among these factors, and possibly provide information on how best to 
intervene to improve health outcomes in this extremely sick population.  For the first clinical 
intervention study, seventeen hemodialysis patients completed a four month intradialytic cycling 
program; exercising during dialysis improved physical functioning and improved cardiovascular 
disease risk as measured by serum alkaline phosphatase and epicardial fat thickness. 
Protein intake during dialysis, either soy or whey protein, attenuated inflammation 
associated with a single dialysis session and reduced the acute phase protein response after a six 
month supplementation program.  Long-term protein intake also improved physical functioning 
and reduced circulating alkaline phosphatase levels, similar to the findings after four months of 
intradialytic cycling.  Taken together, these data suggest modest benefits of intradialytic exercise 
and protein supplementation on functional outcomes in this critically ill population.  Future 
directions include investigating the combined effects of intradialytic protein and exercise in 
maintenance dialysis patients, as the complexity of the disease suggests multiple therapeutic 
strategies may be necessary to improve health outcomes and quality of life for this population. 
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CHAPTER 1 
 
STATEMENT OF PROBLEM & SIGNIFICANCE 
 
The number of dialysis patients in the United States is expected to double in the next 30 
years. At this stage of Chronic Kidney Disease (CKD), a person must undergo dialysis and 
remain on it for life in the absence of a kidney transplant.  After reaching CKD Stage 5, an 
individual is more likely to die from cardiovascular disease (CVD) than kidney failure, and the 
rates of CVD are extremely high in this population.  The increase in CVD risk seems to be due in 
part to an increase in mineral deposits in the arteries that lead to stiffer arteries and contribute to 
plaque formation and development.  In addition, dialysis patients are extremely prone to a bone 
condition known as Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD).  This 
disorder represents a large increase in fracture risk for this population compared to healthy 
adults.  The increase in mineral in the arteries and the decrease in mineral from the bone seem to 
be related, and may be caused by the impaired ability of the kidneys to regulate minerals in the 
body.  Both the cardiovascular and bone complications in this population add to the decreased 
quality of life and functioning experienced by dialysis patients. 
Many of the drug treatments currently prescribed to these individuals will treat one 
condition at the expense of the other, leading to additional soft tissue calcification or unwanted 
loss of mineral from the bone.  Furthermore, treatment of dialysis patients accounts for a 
disproportionately large amount of the Medicare budget.  Current therapies are very costly and   
new approaches are needed that could potentially address the conditions associated with CKD 
and dialysis treatment.   
From a public policy perspective, intradialytic oral protein supplementation represents a 
low-cost, easy to administer treatment strategy that could potentially prevent CVD and bone 
disorders in dialysis patients.   In addition, many dialysis patients experience protein malnutrition 
for a variety of reasons including acute inflammation and catabolism associated with the dialysis 
treatment procedure, making protein supplementation an appropriate target treatment for this 
patient group.  In fact, the National Kidney Foundation recommends an increase in protein intake 
for these individuals to 1.2 g protein/kg of body weight compared to the 0.8 g protein/kg body 
weight recommended to the general adult population.  This level of protein was determined from 
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small nitrogen balance and metabolic studies, and the effect of this recommendation on co-
morbid disease outcomes in this population is unknown. 
Additionally, the importance of a physically active lifestyle for physical and 
psychological health in the general population as well as in dialysis patients is well established. 
In spite of the many known benefits of physical activity, surveys have shown that < 40% of 
nephrologists regularly counsel their patients on physical activity participation, and < 5% 
provide written materials on physical activity to their patients.  Not surprisingly, physical activity 
levels are extremely low in dialysis patients and the benefits of intradialytic exercise training on 
functional outcomes in unclear.         
 Owing to the large number of complications with this population, very little nutritional or 
exercise training research has been done, although it is desperately needed for these patients.  It 
is the goal of this research to study safe, effective, and reasonable diet and lifestyle modifications 
for patients undergoing dialysis to reduce the development of co-morbid diseases and improve 
their quality of life.   
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CHAPTER 2 
LITERATURE REVIEW 
Chronic Kidney Disease: Overview   
Chronic kidney disease (CKD) is a progressive inflammatory disorder that affects 
approximately 13% of adults in the U.S, and the prevalence is increasing rapidly1.  The diagnosis 
of kidney disease falls into five stages depending on the glomerular filtration rate with CKD 
Stage 5 representing a GFR < 15 mL/min/1.73m (Table 1, below).  This advanced stage of 
kidney disease, defined as kidney failure treated with dialysis or transplantation, increased in 
incidence by 43% in the United States in the decade following 19912.  Currently 26 million 
Americans suffer from CKD, and with diabetes and hypertension as the two leading causes of 
CKD, millions more are at high risk for developing kidney damage.  Advanced CKD is 
associated with a variety of metabolic disturbances that increase morbidity and mortality 
including increases in serum creatinine, blood urea nitrogen, urine protein, parathyroid hormone 
and decreases in hemoglobin, serum albumin, and disturbances of calcium, phosphorus, and 
potassium.  In addition, protein malnutrition, muscle wasting, bone disorders, and cardiovascular 
complications are especially common, and these co-morbidities greatly reduce physical function 
and quality of life in dialysis patients. Furthermore, 2/3 of patients die within 5 years of initiation 
of long-term dialysis treatment, mostly of cardiovascular disease (CVD)3, and survival has not 
increased substantially in the past two decades4 despite improvements in dialysis therapy. These 
data clearly indicate that new therapeutic approaches are needed to address the many co-morbid 
conditions associated with advanced kidney disease. 
 
Table 2.1:  Stages of Chronic Kidney Diseasea 
Stage Description GFR (mL/min/1.73 m2) 
1 Kidney damage with normal or high GFR ≥ 90 
2 Kidney damage with mildly decreased GFR 60-89 
3 Moderately decreased GFR 30-59 
4 Severely decreased GFR 15-29 
5 Kidney Failure requiring dialysis or transplant <15 (or dialysis) 
a=adapted from National Kidney Foundation Guidelines, 2002© 
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Standard of Care for Nutrition and Dialysis 
Patients undergoing maintenance hemodialysis require a comprehensive nutritional 
standard of care plan.  The goals of the nutritional management of CKD at this stage (Stage 5) 
include preserving protein and nutritional status, minimizing complications and symptoms 
associated with CKD, and maintaining blood chemistries within recommended ranges. 
Nutritional management should follow the Nutrition Care Process developed by the American 
Dietetic Association.  The important components of a care plan include management of mineral 
intake due to deranged mineral metabolism, limiting of protein intake, managing anemia, 
controlling acid-base balance, and preventing malnutrition, specifically protein-energy 
malnutrition.  The most commonly used clinical indicator of nutritional status in hemodialysis 
patients is serum albumin levels, as hypoalbuminemia is highly predictive of mortality in 
hemodialysis patients5.  Serum prealbumin and creatinine are also routine biochemical markers 
of nutrition status, and along with anthropometric measurements, diet records, and other 
subjective measures, allow for assessment and management of protein and energy nutritional 
status in this population.  Albumin levels below the reference range determined by the National 
Kidney Foundation Kidney Disease Outcomes Quality Initiative of 3.5-5.0 mg/dL indicate 
additional nutrition support may be required; patient education and dietary counseling represent 
the first steps in correcting nutritional deficiencies, however, other methods including tube 
feeding, oral supplementation, or intravenous feeding may be required. 
Patients are instructed to restrict their intake of  fluid, phosphorus, potassium, and sodium 
to prevent fluid retention as well as the development of comorbid conditions including bone 
disorders and CVD.  The current recommendation to prevent protein-energy malnutrition is 1.2 
grams per kilogram body weight of protein, with 50% of the protein being of high biological 
value.  Overall caloric recommendations for this population are 35 kcalories per kilogram body 
weight per day for individuals under the age of 60, and 30-35 kilocalories per kilogram body 
weight per day for individuals over age 60.  The increase in protein and energy requirements 
accounts for the increase in energy expenditure associated with the dialysis procedure, and is 
intended to prevent protein-energy malnutrition in these patients.  Due to the restrictive nature of 
this diet, frequent dietary counseling and patient education sessions are recommended for 
hemodialysis patients to prevent development of CKD co-morbidities.        
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Protein Malnutrition and Physical Functioning in CKD   
Protein-energy malnutrition is very common in dialysis patients, with the incidence rate 
ranging from 25% to 75% in different studies6-9. There are a variety of reasons for this, including 
poor nutrient intake, physical illnesses affecting gastrointestinal function, protein losses during 
dialysis, and elevated whole body and skeletal muscle protein catabolism that occurs primarily 
during dialysis (reviewed in10). Protein malnutrition is associated with a loss of lean mass and 
declines in physical function in hemodialysis patients. These functional declines reduce physical 
activity levels, which exacerbates the development of co-morbidities like CVD and bone 
disorders. This cycle of disease and disability greatly reduces the quality of life (QOL) and 
increases mortality in dialysis patients (reviewed in11, 12). To mitigate these problems, the 
National Kidney Foundation recently recommended an increase in protein requirement to 1.2 
g/kg/day for hemodialysis patients in comparison to the 0.8 g/kg/day recommended for healthy 
adults; this represents a recommended intake double the amount recommended for earlier stages 
of CKD to preserve renal function at 0.6 g/kg/day.  The increase in protein recommendation 
applies immediately after initiation of renal replacement therapy, and patients often have 
difficulty switching to a recommended high-protein diet from months or years on a low-protein 
diet during earlier stages of CKD.  The recommendation of 1.2 g/kg/day was based on several 
small prospective nutritional-metabolic studies indicating this intake level is necessary to ensure 
neutral or positive nitrogen balance in most dialysis patients10 but the effect of this 
recommendation on functional disease outcomes is unclear.  Scott et al recently found in a non-
controlled study that three months of intradialytic supplementation with Nepro, a renal nutrition 
supplement (containing 425 kilocalories, 19.1 grams of protein, 39.4 grams of carbohydrates, 
and 22.7 grams of fat per 8 fluid ounce serving) improved one parameter of QOL as assessed by 
the Kidney Disease Quality of Life-Short Form13.  However, no studies have assessed whether 
increasing protein intake improves lean mass, muscle strength, physical function, or other 
clinical endpoints. 
 
Cardiovascular Disease:  Leading Cause of Death in CKD Patients   
CVD is the leading cause of death in CKD patients, and the risk increases as CKD 
becomes more severe. Cardiovascular events are 10 to 30 times greater in patients with renal 
failure than in age- and sex-matched subjects in the general population14, and CVD is responsible 
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for greater than 50% of premature deaths in dialysis patients15 and this increased risk cannot be 
explained by traditional CVD risk factors including elevated cholesterol, age, gender, and 
hypertension16. A primary reason for this increased CVD risk is the excessive vascular 
calcification (VC) in dialysis patients17-19. Calcification is part of a remodeling of the vascular 
wall in CVD that leads to deleterious functional outcomes, including increases in arterial wall 
intima-media thickness (IMT) and stiffness, endothelial dysfunction, changes in atherosclerotic 
plaque stability, and a variety of clinical end points, including left ventricular hypertrophy 
(LVH)20, 21, myocardial infarction (MI)22-24, poor surgical outcomes25, and CVD mortality22, 26, 27. 
VC is rare in individuals with normal renal function under 40-50 years of age, but clinically 
significant levels develop before the age of 30 in many dialysis patients28, 29 and tend to progress 
rapidly30-34. For example, Stompor et al. found that median coronary artery calcium (CAC) 
scores increased 4-fold after just 1 year in dialysis patients34. In general, dialysis patients have a 
2 to 5 fold increase in CAC levels compared to age-matched subjects with angiographically 
proven CVD33. 
 
Abnormal Mineral Metabolism in CKD:  Vascular Calcification and Bone Disorders  
CKD also is associated with a complex metabolic bone remodeling disorder known as 
chronic kidney disease-mineral and bone disease (CKD-MBD)35. In normal individuals, serum 
calcium and phosphorus levels are tightly controlled, but this control is disrupted in CKD 
patients due to a variety of factors. Diseased kidneys have a decreased capacity to produce the 
activated vitamin D, which leads to a malabsorption of calcium from the intestine that stimulates 
the parathyroid glands to release parathyroid hormone (PTH).  PTH release is also stimulated by 
reduced phosphorus excretion from damaged kidneys.  This elevation in PTH (secondary 
hyperparathyroidism) stimulates the resorption of calcium from bone, leading to low bone 
density and strength, as well as to ectopic mineral deposition36.  
Renal bone disease can present as either high- or low-turnover bone disease. 
Hyperparathyroidism in CKD is normally associated with high-turnover bone disease. However, 
over-suppression of PTH caused by a variety of factors, including high calcium intake (through 
diet or calcium-based phosphate binders), excessive vitamin D therapy, diabetes, and aging37 can 
result in slow bone turnover. Both forms of renal bone disease result in low bone density and 
 
 
7 
reduced bone strength, and hemodialysis patients over 50 experience a 4-fold increase in relative 
risk of fracture compared to age-matched controls38. 
 
Relationship between Vascular and Bone Disorders in CKD 
Many CKD patients have low BMD and excessive VC. Historically, these have been 
considered independent disorders, but there is emerging evidence that the loss of mineral from 
bone and calcification of the vasculature are mechanistically linked. Once thought to be a passive 
precipitation of mineral, VC is now recognized as an active, regulated process with many 
properties similar to bone formation39-41. In response to a variety of stimuli, vascular smooth 
muscle cells (VSMC) are stimulated to differentiate into an osteoblast-like phenotype41 capable 
of producing a bone-like matrix and mineralizing in the presence of calcium and phosphorus42. 
This process appears to be regulated by proteins secreted from VSMC and endothelial cells that 
either promote or inhibit calcium and phosphate precipitation and the formation of 
hydroxyapatite crystals43. Dialysis patients have abnormal circulating levels of several mineral 
regulatory proteins that may promote mineral loss from bone and its deposition in the 
vasculature, including fetuin-A, matrix Gla protein, osteoprotegerin, and bone morphogenetic 
protein-2a44-46. In particular, circulating levels of fetuin-A, an inhibitor of ectopic calcification47, 
are reduced in CKD patients, and this has been correlated with excessive VC in this population45. 
The expression profile of these proteins and their subsequent effect in the vasculature and bone 
may be mediated in part by traditional CVD risk factors48, including elevated glucose levels49, 
high density lipoprotein-cholesterol (HDL-C)50, inflammatory variables51, and oxidized low-
denisty lipoproteins (LDL)52, 53, as well as novel risk factors in CKD patients such as 
hyperphosphatemia54 and malnutrition55. Therefore, factors which modify traditional CVD risk 
factors or improve nutritional status could alter the expression of these mineral regulating 
proteins, thereby influencing the rate and extent of mineral deposition in the vasculature, or 
mineral loss from bone. 
 
Chronic Inflammation:  Cause and Consequence of CKD Co-morbidities 
CKD is a chronic inflammatory condition, as reflected in dialysis patients by elevated 
circulating levels of acute phase proteins such as c-reactive protein (CRP), and pro-inflammatory 
cytokines such as interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-a)56-59. This 
 
 
8 
excessive inflammation is believed to be both a cause and consequence of many of the co-
morbidities associated with CKD, including protein malnutrition and muscle wasting, CVD, and 
bone disorders56. Inflammation is believed to promote malnutrition and muscle wasting through 
a variety of mechanisms, including increased skeletal muscle protein catabolism, cytokine-
mediated hyper-metabolism, suppression of nutrient intake, and disruption of the growth 
hormone and insulin-like growth factor-1 (IGF-1) axis, which may prevent skeletal muscle 
anabolism56, 60, 61. 
It is well-established that inflammation plays a significant role in the development and 
progression of atherosclerotic CVD in non-uremic populations62. Recent evidence also suggests 
that inflammatory mediators, including oxidative stress, CRP and pro-inflammatory cytokines 
promote VC63 and are associated with cardiovascular complications in CKD patients56, 64-67. For 
example, TNF-α can induce mineralization of calcifying vascular cells in vitro68, and co-culture 
of these cells with macrophages, a primary source of proinflammatory cytokines, also increases 
vascular cell mineralization69. In humans, elevated CRP has been associated with increased VC 
in studies in both normal70 and uremic populations29. This may be due in part to inflammation-
induced reductions in fetuin-A71, an inhibitor of VC.   
Inflammation also is implicated in the development of renal bone disease56, 72, 73. For 
example, IL-6, which is expressed by both inflammatory cells and osteoclasts, has been shown to 
promote bone resorption in patients with renal osteodystrophy73, and also has been implicated in 
high bone turnover in multiple myeloma74 and estrogen deficiency75. Furthermore, bone loss in 
rheumatoid arthritis results from the release of metalloproteinases and the pro-inflammatory 
cytokines interleukin-1 (IL-1) and TNF-a76. Elevated CRP levels also are associated with low 
BMD in both normal77 and uremic72 populations. Taken together, these findings suggest that the 
chronic inflammation associated with advanced CKD promotes the development and progression 
of many of the co-morbidities that reduce the QOL and increase mortality rates in this 
population. 
 
Current Approaches to Treat Vascular and Bone Disorders in CKD Are Ineffective 
Numerous pharmacological therapies and nutritional approaches are commonly used in 
an effort to reduce the incidence or severity of CKD co-morbidities. To prevent protein 
malnutrition and muscle wasting, oral, enteral, and parenteral nutrition, anabolic steroids, 
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experimental growth factors, and anti-inflammatory medications78 are often prescribed. While 
many of these treatments have significant benefits, malnutrition and wasting in CKD remains a 
significant problem, indicating that alternative treatment strategies are clearly needed.  Vitamin 
D analogs and phosphate binders are often prescribed to prevent hyperparathyroidism that 
promotes bone disorders in CKD patients, but both may have significant adverse side effects on 
the vasculature. Both vitamin D79, 80 and calcium-based phosphate binders20, 28 have been shown 
to increase VC in rodents and humans, possibly by increasing the calcium-phosphate product (Ca 
X P), a well-established VC risk factor81. Recently developed non-calcium binders (e.g., 
Sevalemer) that do not increase the Ca x P product have been shown to inhibit the progression of 
VC in some studies31, 82 but have not prevented significant VC accumulation in others83. There 
also are numerous concerns regarding costs84-87 and side effects associated with Sevalemer, 
including low tolerance due to gastrointestinal distress85, 88, 89 worsening of metabolic acidosis90, 
hyperkalemia91, and a variety of drug-to-drug interactions92-94. For these reasons, the efficacy of 
Vitamin D therapy and phosphate binders to prevent hyperparathyroidism and its clinical 
manifestations in dialysis patients is still in question95 and alternative therapies are clearly 
needed. 
 
Oral Intradialytic Protein Supplementation:  Little is Known  
Multiple strategies have been used to increase protein intake in dialysis patients, but little 
is known about the efficacy of these different approaches on clinical outcomes. Most dialysis 
patients receive nutritional counseling to increase dietary protein intake at home, but this 
approach has generally been unsuccessful in restoring nutrient intake to recommended levels, 
primarily due to low compliance96, 97. To improve compliance, intradialytic parenteral or oral 
supplementation has been recommended, as this allows intake to be closely monitored. 
Furthermore, intradialytic supplementation may be particularly efficacious in improving protein 
balance since it is provided during the time when protein catabolism is at its peak10, 98, 99. Studies 
have shown that both parenteral100-102 and oral96, 103, 104 intradialytic supplementation improve 
protein homeostasis, increase serum albumin and prealbumin levels, and have anabolic effects on 
skeletal muscle. However, oral supplementation is much more practical than parenteral due to 
high costs and restrictions on the use of parenteral nutrition by Medicare and other insurance 
providers. Despite this, no studies have examined if oral intradialytic protein supplementation 
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has a significant effect on muscle wasting and physical function, or if it inhibits the inflammation 
associated with malnutrition and muscle catabolism during dialysis. 
Because protein malnutrition in dialysis patients promotes inflammation, it has been 
suggested that improving nutritional status may help prevent inflammation60. If so, this could 
have a beneficial effect on many CKD co-morbidities influenced by inflammation, particularly 
CVD56, 72. Indeed, a low protein diet increases VC in uremic rats105, and malnutrition in CKD is 
associated with low circulating levels of the VC inhibitor fetuin-A55, which is known to be 
reduced by chronic inflammation46. This suggests that protein supplementation could potentially 
inhibit VC in uremic/dialysis patients by reducing inflammation. Importantly, Shinaberger et al. 
recently found that both low protein intake and a reduction in protein intake over time are 
associated with increased risk of all-cause and CVD mortality in dialysis patients106. However, 
protein intake in this study was assessed using normalized protein nitrogen appearance (nPNA), 
a surrogate marker of protein intake whose precision has been questioned106, and no studies have 
directly examined the efficacy of oral protein supplementation in dialysis patients on VC or other 
cardiovascular abnormalities.  Another recent study reported that time on dialysis was associated 
with improvements in nutritional status and a trend towards a reduction in inflammatory 
variables over a three year period107.  The authors concluded that time on dialysis was not 
necessarily associated with a decline in nutritional status or increase in inflammation; however, 
they failed to mention in the methods section that patients routinely received an intradialytic 
meal containing 25-30 grams of protein.  This study suggests that routine intradialytic protein 
intake may attenuate the decline in nutritional status and increased inflammatory state associated 
with long-term dialysis treatment; however, this study lacked a control group and failed to 
provide information on subject compliance for this intradialytic meal and more well-controlled 
studies are clearly needed.      
Protein supplementation also may have beneficial effects on bone health by modifying 
insulin-like growth factor-1 levels or activity. Though circulating levels of IGF-1 are typically 
normal in dialysis patients, its bioavailability is often reduced due to an excess of high affinity 
IGF binding proteins108. Both animal and human studies have shown that dietary protein intake 
positively influences bone formation in non-uremic populations by increasing the production and 
action of IGF-1109. However, no studies have examined the effects of protein supplementation on 
IGF-1 levels or bone health in dialysis patients. 
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Potential Role for Soy in Improving Cardiovascular Disease Risk and Measures of Bone 
Mineral Density 
 A non-pharmacological approach that has shown promise in some studies in improving 
risk factors for both CVD and bone disorders is the consumption of soy protein rich in 
isoflavones.  Studies in animal models clearly demonstrate benefits of soy protein and/or 
isoflavones in reducing atherosclerosis110 and increasing bone mineral density (BMD)111, 112.  As 
for CVD, soy isoflavones may reduce long-term CVD risk by several mechanisms; studies have 
shown that soy supplementation induced beneficial blood lipid changes113, 114 and exerts 
regulatory effects on blood pressure.  In addition to the mechanisms listed above, soy protein 
supplementation may have effects on cardiovascular disease that are specific to CKD.  For 
example, soy supplementation has been associated with reduced oxidized-LDL in hemodialysis 
patients115, reduced urinary albumin excretion and LDL/HDL cholesterol ratio116  in patients 
with diabetic nephropathy, and preservation of renal function in moderate kidney disease116, 117.  
In addition, studies have shown that soy/isoflavone supplementation impacts traditional CVD 
risk factors including an inverse association with plasma CRP118 in CKD and an increase in 
osteoprotegerin119.  Osteoprotegerin (OPG), a mineral regulatory protein, inhibits bone 
resorption by binding the OPG receptor on osteoclasts and also appears to inhibit calcification in 
the vasculature.   
However, many studies have shown no effect of soy supplementation120-122 on CVD risk and 
a recently published review indicates that the benefits of soy in humans may be more modest 
than suggested by the animal studies123. Recently, much attention has been given to the fact that 
the effects of soy protein intake seem to dependent on the biotransformation of isoflavones by 
gut bacteria.  Isoflavones can be converted to metabolites in the gut, some of which have 
estrogenic properties while others do not.  Specifically, daidzein is converted to the estrogenic 
equol by gut bacteria, which binds to the estrogen receptor β with high affinity124.  Studies have 
shown that people who produce equol shown an enhanced response to soy protein feeding, 
suggesting that equol may be more metabolically active than the isoflavones or other 
metabolites.  However, studies estimate that only about 11-30% of the population can produce 
equol from gut bacteria125, which may explain why soy supplementation studies show little to no 
effect on outcomes of interest.  Furthermore, most animal species are equol-producers, which 
may explain why the benefits of soy are more clearly demonstrated in animal models.  However, 
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soy isolate supplementation has not been looked at in the context of vascular calcification and 
the related bone mineral disorders, and this represents a novel, promising, and appropriate 
therapeutic target based on the potential of soy to modify risk factors for these diseases.    
 
Differences Between Whey and Soy Protein 
Dialysis patients clearly have increased protein needs due to the acute catabolic effects of 
the dialysis procedure, increased energy expenditure during dialysis treatment, decreased 
appetite, and a variety of other reasons10.  Both whey and soy proteins are high quality protein 
sources with similar digestibility and absorption kinetics126.  However, differences in the efficacy 
of protein supplementation with regards to physical functioning, CVD, and bone disorders differ 
between plant and animal proteins.  Whey protein contains a higher amount of essential amino 
acids compared to plant proteins, including a higher ratio of the branch-chain amino acids 
leucine, isoleucine, and valine127  Leucine concentrations are especially important during a 
highly catabolic condition, as high amounts of leucine have been shown to potently stimulate 
muscle synthesis and inhibit protein breakdown in skeletal muscle and liver (reviewed in128).  
Protein supplementation, regardless of the protein source, during dialysis treatment will increase 
substrate availability, but whey protein may have the greatest impact on the ratio of protein 
synthesis to turnover leading to greater protection of lean body mass in patients with protein 
malnutrition.  Conversely, Candow et al showed soy protein to be as effective as whey protein 
for promoting increase in lean body mass after resistance exercise, and soy protein may stimulate 
muscle accretion by increasing the amino acid pool129.   
While soy protein has been widely discussed for its purported CVD-lowering effects 
including reductions in plasma lipids, the role of whey protein in CVD risk reduction is less 
clear.  However, studies have shown that whey peptides exert anti-hypertensive properties130, 
anti-inflammatory effects in mouse model of dermatitis131, and anti-oxidant properties in a model 
of experimental brain injury132.  These data suggest that during conditions of high inflammation 
and oxidative stress, such as kidney failure, whey protein supplementation may impact CVD 
outcomes through modifications of related risk factors.  However, few studies exist regarding the 
effects of whey protein on CVD in humans and it is unclear from these studies if the reduction in 
risk was due to whey-specific properties or protein intake in general.   
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Similarly, soy protein has been given more attention in relation to bone disorders due to 
soy isoflavones and other estrogenic components.  However, whey protein, or increased protein 
intake in general, may protect against bone loss associated with a variety of conditions.  Chen at 
al demonstrated that whey protein increased bone density in intact and ovariectomized rapidly 
growing female rats, but that a greater increase was seen in the animals receiving soy protein 
containing isoflavones133.  Furthermore, milk basic protein (MBP), a component of whey, can 
promote proliferation and differentiation of osteoblasts both in vitro and in vivo (reviewed in134) 
and may inhibit bone resportion.  Other studies have shown no effect of whey protein135 on bone 
density and the relationship between whey protein intake and bone health remains unclear.  
Furthermore, the differences between soy and whey protein intake have not been considered in 
the context of malnourished dialysis patients, and more information is needed.   
 
Intradialytic endurance exercise for improvement of functional outcomes   
 In recent years, numerous studies have demonstrated that intradialytic exercise training 
has beneficial effects on physical function and QOL, but surprisingly few studies have examined 
its effect on other clinical outcomes, particularly CVD.  Intradialytic endurance exercise has 
been shown to help maintain muscle strength and joint structure and function, improve balance 
and gait speed, reduce the risk of falling, and help maintain independent living status (reviewed 
in136).   Very few studies have examined the efficacy of intradialytic endurance exercise training 
on either CVD risk factors or functional CVD outcomes, and most of those were very small 
and/or did not include a control group (reviewed in137).  For example, Deligiannis et al. 
demonstrated that 6 months of supervised endurance exercise training improved left ventricular 
systolic function138, and Mustata et al139 showed that 3 months of endurance exercise reduced 
arterial stiffness, though there was no control group in this study.  Importantly, there have been 
no randomized, controlled clinical trials in hemodialysis patients to study the effects of exercise 
training on either traditional CVD risk factors or functional CVD outcomes such as arterial 
stiffness, IMT, LVH, or VC136.   
 There are a variety of mechanisms by which exercise training may inhibit CVD outcomes 
in hemodialysis patients.  First, it is well established that exercise training in non-dialysis 
populations improves traditional risk factors for atherosclerosis such as hypertension, plasma 
lipids, glucose and inflammatory variables140.   Many of these same factors may increase the 
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development of VC and arterial stiffness34, 52, 53, 141-143, so it is reasonable to assume that exercise 
training may also reduce VC and arterial stiffness by improving the CVD risk factor profile.  
Exercise training also has been shown to improve phosphate removal during dialysis144, 
indicating a novel mechanism by which exercise training may inhibit VC, and thus, arterial 
stiffness,  in hemodialysis patients.    
   
Physical activity levels and quality of life in dialysis patients.  
 The importance of a physically active lifestyle for physical and psychological health in 
the general population145 as well as in dialysis patients136 is well established. In spite of the many 
known benefits of physical activity, surveys have shown that < 40% of nephrologists regularly 
counsel their patients on physical activity participation, and < 5% provide written materials on 
physical activity to their patients146.  Not surprisingly, physical activity levels are extremely low 
in dialysis patients – data from the Renal Exercise Demonstration Project found that ~ 60% of 
hemodialysis patients participate in no physical activity beyond basic activities of daily living147.  
More importantly, accelerometer data indicates that average physical activity levels in dialysis 
patients are markedly lower than activity levels in sedentary healthy controls148.  Educating 
nephrologists and their patients as to the benefits of increasing physical activity levels in this 
population would appear to be an important health goal.   
 With chronic conditions such as renal failure, functional limitations, disability, and co-
morbidity increase, often resulting in compromised physical, emotional, and psychological well-
being and QOL. The increasing number of adults with CKD and other chronic disorders has 
caused public policy to be directed at ways to maintain the independence, societal worth, and 
physical and mental well-being of this group. In essence, we have moved from simply trying to 
add quantity to life towards adding quality to those years of life. There is increasing evidence to 
suggest that physical activity interventions may represent an effective behavioral strategy for not 
only attenuating functional decline and reducing risk of disease and disability149-151 but also for 
enhancing psychological well-being and QOL across the lifespan152, 153.  Similar benefits on 
psychological well-being and QOL have been noted with intradialytic exercise in CKD 
patients147, 154, 155 ; however there is a lack of large-scale, interdisciplinary, randomized, 
controlled trials targeting such outcomes156.   Such research is needed to conclusively 
demonstrate the clinical importance of intradialytic exercise, which may influence current 
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standard clinical practice among nephrologists and, as such, improve the health and quality of 
life of this vulnerable cohort. 
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CHAPTER 3 
 
INTRADIALYTIC EXERCISE TRAINING AND CHRONIC KIDNEY DISEASE  
CO-MORBIDITIESa 
 
 Patients with chronic kidney disease (CKD) receiving maintenance hemodialysis 
treatment suffer from a variety of co-morbid diseases, many of which may be mechanistically 
linked. Muscle catabolism and wasting is especially common, and these lead to reduced muscle 
strength, declines in physical function, and low levels of physical activity136. Physical inactivity 
exacerbates these functional declines, and also promotes cardiovascular disease (CVD).  This 
cycle of disease and disability greatly reduces the quality of life (QOL) and increases mortality 
rates in hemodialysis patients. 
Introduction 
 CKD is an chronic inflammatory condition, as reflected by elevated circulating levels of 
acute phase proteins such as C-Reactive Protein (CRP), and pro-inflammatory cytokines such as 
interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α)60.  Excessive oxidative stress 
associated with uremia is believed to play a critical role in the development of the chronic 
inflammation in CKD patients157.  Oxidative stress contributes to inflammation in part by 
activating the nuclear transcription factor NF-κB, which mediates the expression of pro-
inflammatory cytokines associated with immune and inflammatory responses158. Inflammation 
and oxidative stress both play a critical role in atherosclerosis development in CKD patients60, 64, 
and also are related to the pathogenesis of functional CVD outcomes, including arterial stiffness, 
increases in arterial wall intima-media thickness (IMT), left ventricular hypertrophy (LVH), and 
declines in cardiac function20, 21.  Inflammation also reduces circulating levels of fetuin-A, a 
reverse acute phase protein that acts as a systemic inhibitor of vascular calcification and arterial 
stiffness159. As a result of these abnormalities, cardiovascular events are 10 to 30 times greater in 
hemodialysis patients than in age- and sex-matched subjects in the general population14.   
 
aThis chapter contains material previous published as follows:  Wilund KR, Tomayko EJ, Wu PT, Ryong Chung H, 
Vallurupalli S, Lakshminarayanan B, Fernhall B. Intradialytic exercise training reduces oxidative stress and 
epicardial fat: a pilot study. Nephrol Dial Transplant. Aug 2010;25(8):2695-2701.  Used with permission of Oxford 
University Press. 
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 Numerous studies have highlighted the importance of adipose tissue in relation to the 
inflammatory burden in CVD, describing the expression and secretion of both pro-inflammatory 
and protective factors, collectively termed adipocytokines160, 161.  More recently, research has 
begun to focus on the unique role of epicardial adipose tissue, a visceral fat depot surrounding 
the heart, on CVD risk.  Like other white adipose tissue, epicardial fat functions as a lipid-storing 
depot, as an endocrine organ secreting hormones, and as an inflammatory tissue secreting 
cytokines. The close proximity of epicardial fat to the adventitia of the coronary arteries and the 
underlying myocardium suggests the possibility that it could play an especially important role in 
the pathogenesis of CVD162.  Indeed, recent studies have shown that the expression and secretion 
of pro-inflammatory cytokines (TNF-α, IL-1B, and IL-6) are increased in epicardial fat, relative 
to subcutaneous fat, in coronary artery disease patients163. This suggests that therapies that 
decrease the amount of epicardial fat may reduce CVD risk.  
 It is well established that endurance exercise training helps reduce fat mass, but there is 
significant controversy regarding whether or not it promotes a reduction in visceral fat over other 
fat depots164.  Recently, epicardial fat was shown to be reduced in young, healthy, obese men 
after 12 weeks of endurance exercise training (jogging)165.  However, functional limitations and 
other factors may limit the intensity at which many hemodialysis patients can exercise136, and it 
is not known if similar benefits would be realized with moderate intensity intradialytic cycling. 
While numerous studies have shown that intradialytic exercise improves physical function and 
quality of life in hemodialysis patients136, 137, 147, 166, surprisingly little is known about the effects 
of endurance exercise training on CVD risk in this population136.  As a result, the objective of 
this study was to evaluate the efficacy of intradialytic endurance exercise training (cycling) on 
factors related to the excessive CVD risk in hemodialysis patients, specifically, markers of 
systemic inflammation (CRP, and Interleukin (IL)-6, and fetuin-A), oxidative stress (lipid 
peroxidation using the thiobarbituric acid reactive substances (TBARS) assay), cardiac structure 
and function and epicardial fat levels (ultrasound).  We hypothesized intradialytic exercise 
training would favorably modify cardiovascular disease risk factors similar to the effects seen in 
healthy populations, and four months of training would improve our primary outcomes, 
specifically cardiac structure (IMT, LVM, epicardial fat thickness) and function (cardiac output 
and ejection fraction).  However, we expect the beneficial effects of exercise in this population to 
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be more modest due to contributions of CKD-related comorbidities including elevated 
inflammation and oxidative stress.     
 
Subjects.  Seventeen patients on maintenance hemodialysis (9 females, 8 males) were recruited 
from the Champaign-Urbana Dialysis Clinic (Champaign, IL). Patients were screened for 
eligibility by administering a health and medical history questionnaire. All participants gave 
written informed consent and this study was approved by the University of Illinois Institutional 
Review Board.  Inclusion/exclusion criteria for patients included the following: 1) age = 30-70 
years; 2) nonsmoking; 3) BMI < 35 kg/m2; 4) no orthopedic problems that prevented cycling 
during dialysis; 5) no chronic obstructive pulmonary disease (COPD), coronary heart failure 
(CHF), or cardiovascular surgery (e.g., coronary bypass, valve replacement, or angioplasty) in 
the past 6 months;  6) medical clearance from a primary care physician; 7) no participation in 
intradialytic exercise training for 6 months prior to recruitment in the study. 
Methods 
 
Study Design. Following recruitment, screening, and baseline testing, eligible subjects were 
randomly assigned to one of two groups: 1) Usual care/control (CON; n=9); 2) intradialytic 
exercise training (EX; n=8).  
 
Exercise Training Intervention. Subjects in the EX group underwent a 4-month intradialytic 
endurance exercise training program. This program consisted of cycling 3 days per week on 
specialized cycle ergometers (Champ-CycleTM; Champion Manufacturing, Inc. Elkhart, IN) 
placed in front of each subject’s dialysis chair. Subjects started the training program by cycling 
at a tolerable pace for 5 minutes during their first exercise session. The duration of exercise 
increased by 5 to 10 minutes per session, depending on each subject’s individual tolerance, until 
they were able to cycle continuously for a total of 45 minutes per session at a rating of perceived 
exertion (RPE) of 12-14 (“somewhat hard”167).  The subjects reached this level of exercise in 
1.8± 0.6 weeks. Subjects maintained this duration and intensity of work for the remainder of the 
4 month intervention. All exercise sessions were attended by study staff to encourage the 
subjects and monitor their response to exercise (e.g., heart rate and blood pressure).  Compliance 
with the exercise protocol was measured as the percentage of exercise sessions successfully 
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completed. To count as complete, a minimum of 75% of the goal exercise time for that session 
had to be performed.  Subjects in the CON group were not given access to cycle ergometers 
during their dialysis sessions.   
 
Clinical Testing and Measurements. At baseline and immediately following the 4 month 
intervention (final testing), all patients underwent a series of tests described below to evaluate 
the effects of the intradialytic exercise program on our primary outcomes. All testing sessions 
were conducted on a “non-dialysis day”, 18-24 hours following a dialysis treatment. All testing 
was analyzed by study personnel blinded to the subject’s group assignment.  
 
Incremental Shuttle Walk Test. Physical performance was measured by distance walked 
during an incremental shuttle walk test (ISWT). The ISWT is a progressive test in which patients 
walk back and forth continuously over a 10 meter course. The walking speed is paced by a series 
of beeps that signal when the subject should have completed the 10 meter walk. The pace is 
progressively increased so that the walking speed at the end of each successive minute is ≥ to: 
1.12, 1.54, 1.88, 2.26, 2.64, 3.02, 3.4, 3.78 miles per hour.  The test was terminated when the 
subject was unable to complete the 10m course before the subsequent beep. The ISWTs were 
performed on non-dialysis days, 18 to 24 hours after a previous dialysis session, and post-
intervention evaluations were performed at least 36-48 hours after any previous exercise bout.   
 
Blood Chemistry. Blood was collected from patients in a non-fasted state from their dialysis 
lines during regularly scheduled (monthly) blood collection times at the clinic, a minimum of 48-
72 hours after any scheduled exercise bout.  Blood collections were performed by trained 
technicians, and blood was collected from the dialysis line immediately after initiating dialysis 
treatment according to the standard protocol of the clinic.  Plasma was collected from blood 
samples by centrifugation, aliquoted, and stored at -80oC until analyzed. To control for variation 
between runs, baseline and final test samples from each subject were analyzed simultaneously. 
Plasma total cholesterol levels were measured using a commercial enzymatic kit (Wako Inc., 
Richmond, VA).  CRP, IL-6 and Fetuin-A were measured in triplicate using commercially 
available enzyme-linked immunosorbet assay (ELISA) kits (hsCRP ELISA #1668Z, Diagnostic 
Automation Inc., CA; Quantikine HS Human IL-6 #HS600B, R&D Systems, MN; Human 
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Fetuin-A ELISA #RD1815, BioVendor, NC).  Serum lipid peroxidation, a marker of oxidative 
stress, was measured by the thiobarbituric acid reactive substances (TBARS) assay, as 
described168. In brief, serum samples were diluted with PBS and incubated with or without 
100mM of 2.2’-azobis, 2-amidinopropane hydrochloride (AAPH), a free radical generator, for 2 
h at 37oC. Lipid peroxidation was calculated by subtracting values obtained in the presence and 
absence of AAPH. 
 Serum potassium, phosphate, calcium, alkaline phosphatase (ALP), calcium-phosphorus 
product (Ca x P product), blood urea nitrogen (BUN) and albumin were measured using an 
autoanalyzer (Olympus, Inc.) by Spectra Labs (Rockleigh, N.J.).  
  
Blood Pressure. Brachial blood pressure was measured using an automatic digital blood 
pressure monitor (Omron IntelliSense HEM-907XL, IL). Subjects were seated for 10 min prior 
to the first reading. Two measurements, 2 min apart, were performed. If these two measurements 
were within 10% of each other, the average of the two measurements was taken as the final 
recorded blood pressure.  If not, a third measure was taken, and the two closest measures were 
averaged. 
 
Echocardiography.  Echocardiography was performed using a multifrequency (1.5-4.25 MHz) 
transthoracic transducer (Acuson Sequoia C512, Mountain View, CA) to assess parameters 
related to cardiac structure and function. To minimize the effect of variations in fluid volume in 
hemodialysis patients, studies were performed 18-24 after a hemodialysis session. Left 
ventricular mass (LVM) was measured by M-mode echocardiography to determine left 
ventricular mass, as described previously 169. LVM index was measured according to the formula 
LVM index = LVM/body surface area. Relative wall thickness was measured as RWT = 
2×(PWTd/LVEDD), where PWTd is the posterior wall thickness at end-diastole and LVEDD is 
the LV dimension at end-diastole.  Myocardial performance index (MPI) reflects both systolic 
and diastolic function of the heart and was measured as MCOT-LVET/LVET where MCOT is 
the mitral valve closure to opening time and LVET is the left ventricular ejection time. Left atrial 
volume was calculated using the biplane area – length method at end ventricular systole with 
precaution taken to avoid foreshortening. The left atrial volume was indexed to body surface area 
to derive left atrial volume index. 
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 The thickness of the epicardial fat layer also was measured by echocardiogram as 
previously described170.  In brief, standard parasternal and apical views were obtained with 
subjects in the left lateral decubitus position. Epicardial fat was identified as the echo-free space 
between the outer wall of the myocardium and the visceral layer of pericardium and its thickness 
was measured perpendicularly on the free wall of the right ventricle at end systole in three 
cardiac cycles 170. Maximum epicardial fat thickness was measured at the point on the free wall 
of the right ventricle along the midline of the ultrasound beam, perpendicular to the aorta 
annulus. The average value of 3 cardiac cycles for each echocardiographic view was considered 
as the epicardial fat thickness. 
 
Statistical Analysis. All statistical analyses were performed using SPSS software and 
significance was based on a two-tailed alpha value of 0.05.  Distribution statistics for the 
residuals were calculated to determine whether assumptions of normality were met (i.e., 
skewness and kurtosis < 2.0). Repeated measures Analysis of Variance (ANOVA) (Group X 
Time) was used to assess group differences in our major outcomes. Main effects were only 
considered when interactions were not significant, as a significant interaction indicates that the 
effect of one independent variable depends on the value of the other.  When significant 
interactions were detected, paired sample t-tests were conducted to determine if values between 
time points differed significantly within each activity group. Correlation analysis was used to 
identify relationships between selected variables of interest.   
 
 Subject characteristics at baseline and final testing are shown in Table 3.1.  The etiology 
of each patient’s renal failure and the presence of underlying CVD are described in Table 3.2.  A 
total of 17 patients were recruited for the study, 9 in CON and 8 in EX.  One subject in EX 
withdrew due to a hip fracture that was unrelated to the exercise intervention, one subject in 
CON withdrew due to moving out of area, and a second subject in CON did not complete the 
baseline shuttle walk test due to a scheduling error. 
Results 
At baseline, the two groups did not differ significantly regarding age, body weight, height, 
body mass index (BMI), months on dialysis, frequency of dialysis sessions, blood pressure, 
physical performance, cardiac function, or hematological variables (Table 3.1).  Due to the small 
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sample size, the mean baseline values varied widely among individuals; however, the differences 
between treatment groups were not significant due to the large variation present within each 
group.  There were no interactive or main effects of activity group and time on BMI, systolic, or 
diastolic blood pressure (Table 3.1).   
There was a significant interaction (p < 0.05) between activity group and time for serum 
TBARS and alkaline phosphatase activity, as they were reduced by 38% and 27%, respectively, 
in EX, but did not change in CON (Table 3.1).   
 There was a significant interaction between activity group and time for ISWT 
performance, as the distance walked during this test increased by 15 % in EX (p = 0.03), but did 
not change in CON (Figure 3.1).  
 There were no interactive or main effects of activity group and time on MPI, LVM index, 
relative wall thickness or LA volume index.  However, there was a significant interaction 
between time and activity group for epicardial fat thickness, as it was significantly reduced in EX 
(-9.8%, p = 0.03), but did not change in CON (0.03%, p = 0.96) (Figure 3.2).  Furthermore, 
when data from both groups were combined, the change in performance on the ISWT was 
inversely correlated to the change in epicardial fat (r = -0.66, p = 0.01) (Figure 3.3), and the 
change in serum alkaline phosphatase level (r = - 0.60, p = 0.02). 
   
The primary findings in this paper were that 4 months of intradialytic exercise training at a 
moderate intensity increased physical performance, and reduced serum TBARS, serum alkaline 
phosphatase, and the thickness of the epicardial fat layer. Furthermore, the change in epicardial 
fat levels was inversely correlated to the change in physical performance. To the best of our 
knowledge, this is the first time that intradialytic exercise has been shown to reduce levels of 
these CVD risk factors in the context of CKD, including the novel risk factor of epicardial fat 
thickness.  These benefits occurred in response to a rather modest amount of exercise: 
intradialytic cycling 3 days per week for 45 minutes at a moderate intensity, an exercise dose that 
is easily achievable by most dialysis patients.  
Discussion 
We also believe this is the first time that the ISWT has been used to measure changes in 
physical performance in dialysis patients in response to intradialytic exercise.  Shuttle walk tests 
are appropriate to assess function in older and diseased people since functional limitations often 
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prevent these individuals from achieving standard criteria of more objective tests (e.g., VO2max 
testing) 136.  The average change in distance walked during the ISWT in the EX group was 45 ± 
16m, which appears to be marginally less than what has been reported following rehabilitation 
programs in COPD patients and other populations, but is still in the range of what is thought to 
be clinically significant171.   
Epicardial fat is a highly inflammatory fat depot surrounding the heart that recently has 
been shown to be a marker for the presence and severity of CVD163, 172.   The close proximity of 
epicardial fat to the adventitia of the coronary arteries and the underlying myocardium suggests 
the possibility that it could play an especially important role in the development of CVD160, 162. 
Evidence indicates that epicardial fat may locally modulate cardiovascular morphology and 
function. Iacobellis et al. showed that epicardial fat is positively correlated with abdominal 
visceral adiposity173, atherosclerosis174, and cardio-metabolic risk170, 175.  As a result, 
interventions that reduce the extent of epicardial fat may have clinical benefit.  Recently, Kim et 
al165 showed that 12 weeks of running at a moderate intensity reduced epicardial fat thickness in 
middle-aged obese men by 8.6%, which was similar to the 9.8% reduction in epicardial fat we 
found in the current study.  However, the study by Kim et al did not include a non-exercising 
control group. Our study confirms and extends the findings of Kim et al by showing that 
moderate intensity exercise training significantly reduces epicardial fat compared to a non-
exercising control group.  Importantly, the reduction in epicardial fat was not correlated with 
weight change, suggesting that epicardial fat may be a very responsive adipose tissue that can 
reduced by relatively modest amounts of exercise in the absence of weight loss.  
Previous studies in patients undergoing coronary artery bypass grafting have shown that 
epicardial fat is highly correlated with inflammation163, 176, and coronary artery disease patients 
have significantly higher levels of inflammatory cytokines (IL-1b, IL-6, and TNFα) released 
from epicardial fat than that from subcutaneous fat 163, 177.  Despite this, we did not see changes 
in any marker of systemic inflammation in response to the change in epicardial fat, including 
traditional inflammatory markers such as CRP and IL-6, or markers of inflammation especially 
important in CKD patients, including albumin and fetuin-A.  This is somewhat surprising, given 
that many, though not all, previous studies have shown that exercise training reduces systemic 
markers of inflammation178, 179.  However, plasma concentrations of circulating inflammatory 
cytokines may not be correlated to inflammation in tissues163, so it is possible that the reductions 
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in epicardial fat affected artery wall inflammation, but this was not captured by measuring 
systemic levels of inflammatory markers.  Furthermore, the small sample size for this study may 
have limited the statistical power to detect changes in these variables.  
Our data are consistent with the cross-sectional study of Hung et al. 180, which showed no 
evidence for a correlation between TNF-a and physical activity levels in hemodialysis patients. 
Castaneda et al. reported that 12-weeks of resistance exercise training reduced CRP and IL-6 
levels in patients with moderate chronic kidney disease 181, but we are unaware of any studies 
that have demonstrated an anti-inflammatory effect of endurance exercise training in 
hemodialysis patients.   We also hypothesized that the levels of fetuin-A would increase after the 
exercise intervention, based in part on our previous work showing that fetuin-A was positively 
correlated with VO2max in older men 182. Fetuin-A is a reverse acute phase protein which is 
reduced with inflammation, and a systemic inhibitor of vascular calcification.  However, fetuin-
A levels did not change in either group in this study, possibly because there was no change in 
other markers of inflammation.  Taken together, these data suggests that the modest anti-
inflammatory effects of exercise training seen in other populations may be insufficient to have 
significant effects on inflammatory variables in dialysis patients, a population with excessive 
inflammatory stresses.   
Excessive oxidative stress is believed to be partly responsible for the increased 
inflammation and CVD burden in hemodialysis patients 157, 183, 184.  The increased oxidative 
stress in hemodialysis patients is mainly attributed to the retention of oxidized solute by the loss 
of kidney function157. Growing evidence indicates that endurance exercise training results in 
reducing O2– production and up-regulating antioxidant enzymes activity 136. Our finding of 
decreased TBARS levels in the exercise group suggests a reduction in the burden of oxidative 
stress due to an increase in serum antioxidant activity, which may help reduce CVD risk in 
hemodialysis patients.  However, TBARS was measured in non-fasted samples, and the potential 
anti-oxidant effect of exercise needs to be confirmed with more robust markers of oxidative 
stress.  
The 27% reduction in serum ALP in EX (Table 3.1) may be clinically significant, as serum 
ALP levels are have been inversely associated with bone mineral density in hemodialysis 
patients185, and positively associated with coronary artery calcification (CAC)186, a complex 
disorder associated with abnormal mineral metabolism39.  In healthy populations, exercise 
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training has been shown to increase serum ALP levels187. By contrast, our data coincides with 
data from Yurtkuran et al188 indicating that physical activity reduces ALP levels in hemodialysis 
patients. This discrepancy may be due to abnormalities in mineral metabolism in the 
hemodialysis population.  Regardless, the reduction in ALP suggests a potential mechanism by 
which intradialytic exercise improves CVD risk and reduces bone disorders in dialysis patients. 
Elevated serum phosphate levels also are believed to contribute to vascular calciﬁcation. 
Vaithilingam et al. previously showed that 1 week of intradialytic cycling reduced serum 
phosphate levels, possibly by improving the perfusion of skeletal muscle during dialysis144.  
However, we did not find changes in phosphorous levels after our 4-month exercise intervention, 
and are uncertain of the reasons for our discrepant findings.   
There were several limitations to our study.  First, our sample size was relatively small, 
which may have limited our ability to detect differences in our primary outcomes due to low 
statistical power.  The limited sample size also did not allow us to control for many factors that 
may have impacted the results, including diabetes status, medications, gender, and race.  
Furthermore, the 4 month intervention may have been too short to improve other CVD risk 
factors, including markers of inflammation, and metrics related to cardiovascular and renal 
function.  Additional research with larger study populations and longer interventions will be 
needed to more thoroughly assess the cardiovascular benefits associated with intradialytic 
exercise training.   We also cannot rule out the possibility that the improvements seen in the EX 
group may be partially attributed to the increased individual attention and social interaction they 
received from the research staff while exercising, despite our best attempts to socialize equally 
with patients in the CON group.  Finally, we collected medication lists at baseline only, so any 
changes in medications (e.g., addition of immunosuppressive medications) that occurred after 
this time may have affected our results.      
In summary, we demonstrated  four months of intradialytic endurance exercise improved 
physical performance, and reduced one marker of serum oxidative stress (TBARS), alkaline 
phosphatase, and epicardial fat levels.  These data suggest potential mechanisms by which 
intradialytic exercise training may reduce CVD risk; including a novel CVD risk factor in this 
population (epicardial fat thickness).  Furthermore, this study adds to the considerable evidence 
providing support for the adoption of intradialytic exercise as a standard component of care for 
hemodialysis patients.   
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Tables 
 
Table 3.1 Subject Characteristics at Baseline and Final Testing. 
CONTROL  EXERCISE 
 Baseline Final  Baseline Final 
Age (yr) 59.0±4.9  60.8±3.2 
Gender  5f, 3 m  4f, 3m 
Time on Dialysis (months) 44.6±12.2  63.3±8.7 
Dialysis prescr iption (h/wk) 9.9±0.9  10.0±1.1 
Diabetic (% ) 50%  43% 
BMI (kg/m2) 29.0±2.0 28.3±1.8  30.1±2.4 30.3±2.5 
SBP (mmHg) 128.6±10.1 153.0±17.2  150.0±2.3 147.1±14.9 
DBP (mmHg) 74.6±5.4 85.7±7.7  74.4±3.2 77.3±8.7 
      
 Serum Parameters     
Cholesterol (mg/dL) 146.7±14.6 136.7±13.1  175.6±23.1 164.5±23.6 
Albumin (g/dL) 3.9±0.14 3.9±0.15  3.8±0.09 3.8±0.06 
Potassium (mEq/L) 4.6±0.16 4.9±0.25  4.8±0.25 4.9±0.30 
Calcium (mg/dL) 9.1±0.26 8.86±0.25  9.1±0.36 8.8±0.59 
Phosphorous (mg/dL) 6.3±0.73 5.9±0.5  5.2±0.39 6.5±0.76 
Ca x P product 58.7±7.47 52.8±5.06  47.6±4.25 60.1±6.84 
ALP (U/L) ++ 102.0±12.6 116.8±14.99  110.5±14.77 87.4±11.34* 
BUN/Creatinine ratio 6.9±0.83 6.6±0.85  6.4±0.52 6.7±0.46 
CRP (mg/L) 5.2±0.78 4.9±0.69  6.2±0.22 6.0±0.67 
IL-6 (pg/mL) 2.9±0.93 2.5±0.44  2.2±0.71 1.8±0.66 
Fetuin-A (ng/mL) 18.2±2.7 19.2±3.26  19.8±1.01 17.6±0.60 
TBARS (μmol/L)++ 7.2±.0.7 6.9±1.31  9.5±1.55 5.9±1.05* 
Hematocr it 36.8±1.9 38.5±0.5  35.1±1.6 38.7±1.1 
  Cardiac Measures  
   
LV MI (g/m2) 172.3±32.62 154.4±25.83  144.0±40.99 127.4±18.17 
Relative Wall Thickness  0.68±0.04 0.63±0.03  0.66±0.08 0.62±0.08 
LA VI 35.5±7.26 27.2±6.70  35.37.24 27.9±5.52 
MPI 0.41±0.04 0.41±0.05  0.37±0.07 0.29±0.03 
 
Data are reported by means ± S.E.M.  ++p<0.05 for an interaction effect between time and 
physical activity group.  *p< 0.05 compared to baseline measure within a physical activity group.  
Ca x P Product = Calcium phosphorus product; CRP= C-reactive protein; IL-6 = Interleukin 6; 
TBARS = Thiobarbituric acid reactive substances; PON = Paraoxonase; ALP = Alkaline 
Phosphatase; SBP and DBP = systolic and diastolic blood pressure, respectively; LV MI = left 
ventricular mass index; LA VI = left atrial volume index; MPI = myocardial performance index. 
h/wk = hours per week undergoing dialysis treatment. 
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Table 3.2:  Etiology of CKD and Underlying Cardiovascular Disease in Study Patients 
 
Etiology of CKD CON (n=8) EX (n=7) 
Unspecified Hypertensive Renal Disease 3 3 
Diabetes with Renal Manifestations Type 2 1 1 
Focal Glomerulosclerosis 1  
Membranous Nephropathy  1 
Diabetes Type 2 without Complication  1 
Scleroderma 1  
Amylodisis  1 
Etiology Uncertain 2  
Cardiac Disease   
Congestive Heart Failure 2 2 
Myocardial Infarction 3  
Enlarged Heart 1  
Heart Murmur  1 
No reported cardiac disease 2 3 
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Figures 
Figure 3.1 
 
Figure 3.1. Performance on shuttle walk test. Patients in both the EX and CON groups had 
physical performance measured at baseline and final testing using an incremental shuttle walk 
test.  Changes in the distance walked during the shuttle walk test for each individual are shown 
on the left, with group averages ± S.E.M. on the right.  Performance on the test increased from 
baseline to final testing in the EX group (p< 0.05), but did not change in the CON group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29 
Figure 3.2 
 
Figure 3.2. Epicardial fat thickness.  The thickness of the epicardial fat layer was measured by 
echocardiography at baseline and final testing in all patients.  There was a significant reduction 
in epicardial fat thickness (-9.8%) in the EX group, but not in CON.  Values are expressed as 
means ± S.E.M. *p<0.05. 
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Figure 3.3 
 
Figure 3.3. Correlation between the change (Δ) in performance on ISWT and the change (Δ) in 
epicardial fat thickness.  When data from both groups (EX and CON) are combined, the Δ ISWT 
was significantly correlated with Δ epicardial fat thickness (r = -0.66, p=0.01).  
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CHAPTER 4 
 
PROTEIN INTAKE AND EXERCISE TRAINING IN A MOUSE MODEL OF RENAL 
INSUFFICIENCYa 
 
Chronic Kidney Disease (CKD) patients have significantly elevated rates of 
osteoporosis189 along with a specific metabolic bone remodeling disorder known as chronic 
kidney disease-mineral bone disease (CKD-MBD) 35 leading to increased fracture risk, mortality, 
and morbidity190.  Elevated parathyroid hormone, common to CKD patients, stimulates 
resorption of calcium from bone, leading to low bone density and strength, as well as to ectopic 
mineral deposition 36.  
Introduction 
The abnormal mineral metabolism is not confined to the bone, but also affects the 
vasculature.  Cardiovascular disease (CVD) is the leading cause of death in CKD patients, and 
the risk may be partially explained by excessive vascular calcification (VC) in CKD patients17-19.  
Historically, loss of mineral from the bone and vascular calcification have been considered 
independent disorders, but there is emerging evidence that they are mechanistically linked;  VC 
is now recognized as an active, regulated process with many properties similar to bone 
formation39-41.   
Most strategies aimed at inhibiting the progression of VC and bone disorders in CKD 
have focused on pharmaceutical interventions known to modify traditional CVD risk factors or 
improve bone density.  However, many of these treatments have substantial side effects and are 
very expensive, indicating the need for additional therapies.  A non-pharmacological approach 
that has shown promise in improving risk factors for both CVD and bone disorders is the 
consumption of soy protein rich in isoflavones.  Studies in animal models clearly demonstrate 
benefits of soy protein and/or isoflavones in reducing atherosclerosis110 and increasing bone 
mineral density (BMD) 111, 112.  As for CVD, soy isoflavones may reduce long-term risk in  
 
aWith kind permission from Springer Science+Business Media: Journal of Bone and Mineral Metabolism, Soy 
protein diet and exercise training increase relative bone volume and enhance bone microarcitecture in a mouse 
model of uremia, 29 ( 2011), 682-690 , Tomayko EJ, Chung HR, and Wilund KR, and any original (first) copyright 
notice displayed with material. 
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humans by improving blood lipids 113, 114 and blood pressure.  However, many studies have 
shown no effect of soy supplementation120-122 on CVD risk and/or bone health in humans, and a 
recently published review indicates that the benefits of soy in humans may be more modest than 
suggested by the animal studies123.  In addition, it is not known if these effects will persist in the 
context of CKD.  
 The benefits of exercise on cardiovascular risk and bone health have been well 
established in healthy populations, but few studies have looked at the effect of weight-bearing 
endurance exercise training for individuals with CKD, particularly in CKD stages 3-4 
representing moderate to severe renal impairment.  Exercise training in populations with normal 
kidney function improves traditional risk factors for atherosclerosis such as hypertension, plasma 
lipids, glucose and inflammatory variables140.  Many of these same factors may increase the 
development of VC, so it is reasonable to assume that exercise training may also reduce VC by 
improving the CVD risk factor profile.  Few studies have considered the effects of exercise 
training on bone health in individuals with CKD, and this is the first study to consider the 
relationship between exercise, bone, and vascular health in a model of CKD.     
Due to the complex pathogenesis of CKD, it has been suggested that multiple therapeutic 
interventions will be necessary and should be used simultaneously to reduce co-morbidities in 
this population191.  Previous animal studies have demonstrated prevention of bone loss and 
reduction of cardiovascular risk with a combination of soy isoflavones and exercise192, 193, but 
this approach has not been examined in a model of kidney disease.  Therefore, the purpose of 
this study was to evaluate the effectiveness of a soy protein diet and exercise training, alone and 
in combination, on vascular and bone measures in a mouse model of moderate to severe renal 
insufficiency.  Apo E-/- mice were chosen because they rapidly develop atherosclerosis when 
placed on a high fat diet due to disordered lipid metabolism, allowing for a study of the 
relationship between CVD and CKD in this model of uremia-induced accelerated 
atherosclerosis194.  Furthermore, Nikolov et al have demonstrated disordered bone metabolism in 
this model195 which allows for the inclusion of this co-morbid condition in our intervention 
study.  We hypothesized both exercise and consumption of a soy protein diet would attenuate 
development of atherosclerotic lesions and bone disorders, and that the effects of the combined 
treatments would be additive.        
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Animals. Sixty female apolipoprotein E-/- (B6.129-Apoetm1Unc/J,  #002052) were obtained from 
The Jackson Laboratories (Bar Harbor, Maine) at six weeks of age and 18-20 grams.  The mice 
were individually housed in plastic cages in a temperature controlled facility and maintained on a 
12:12 hour light/dark cycle.  Animals were provided ad libitum access to standard rodent chow 
and water.  Animals were adapted to diet and environmental conditions for two weeks before 
initiation of the study protocol.  All experiments and protocols were approved by the Illinois 
Animal Care and Use Committee at the University of Illinois, Urbana-Champaign.   
Materials and Methods 
 
Surgical Creation of Uremia.  At 8 weeks of age all mice underwent a two-step surgical 
procedure to induce uremia.  Animals were anesthetized using a combination of oxygen and 1-
3% isoflurane.  For the first procedure, the right kidney was approached through a 2cm long 
lumbar incision and was exposed by fine dissection of the surrounding tissues. The anterior and 
posterior poles of the kidney were resected, leaving the middle segment of the kidney intact.   At 
10 weeks of age, following a two week recovery, a total nephrectomy of the left kidney was 
performed by ligation of the renal artery with a 5-0 silk suture followed by excision of the 
kidney.  Establishment of the surgical model was determined by plasma urea concentrations 
between 12 and 25 mM (normal mouse plasma urea ≤ 8 mmol/L). At 12 weeks of age, after an 
additional two weeks recovery, animals with urea levels > 12 mmol/L were randomized into one 
of the following four groups for the 16 week intervention:  casein diet, sedentary (Cas/Sed, n=16 
); soy protein diet, sedentary (Soy/Sed, n=18); casein diet, exercise-trained (Cas/Ex, n=14); soy 
protein diet, exercise-trained  (Soy/Ex, n=12).  The different number of animals in each group 
reflects the number that survived the high-intensity surgery until the completion of the 16 week 
intervention.         
 
Diet and Exercise Protocol. The compositions of the experimental diets are outlined in Table 
4.1.  Both diets were purified diets that derived 15% of kilocalories from fat and differed in the 
protein source.  The protein content in the diet was chosen based on the level of protein provided 
in standard rodent chow.  The  soy protein diet (TD.06653 Harlan Teklad, Madison, WI) 
contained 20.0% w/w soy protein isolate and provided 250 mg of isoflavones/kg diet while the 
control diet (TD.06650 Harlan Teklad, Madison, WI) contained 20.0% w/w casein and contained 
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no isoflavones.  The diets were specially formulated by Harlan Teklad for this study to be 
approximately matched for sulfur amino acids, available phosphorus, calcium, sodium, 
potassium, magnesium, iron, and choline.  The animals received standard chow until 12 weeks of 
age (2 weeks after second surgery) at which time they were randomized to a purified 
experimental diet.   
The exercise protocol consisted of running on a motorized treadmill (Jog-a-Dog, Toledo, 
Ohio) 5 days per week for 45 minutes/day during the intervention period. The mice were 
acclimated to the treadmill exercise such that by the second week of training they ran at 15 
m/min.  This corresponds to 60-75% VO2max in C57BL/6J mice196, which represents “moderate-
intensity” exercise in these animals197-199.  Negative reinforcement was not used but rather gentle 
prodding with a blunt instrument was employed to encourage the mice to exercise.  Sedentary 
mice were not provided access to the treadmill.  
 
Serum assays. Fasting blood samples were drawn from the retroorbital vein on two occasions:  
prior to the start of the dietary intervention and prior to euthanasia.  Plasma and serum was 
collected by centrifugation, aliquoted into microfuge tubes, and stored at -80°C until analyzed.  
Plasma urea (BioAssay Systems, Hayward, CA) and total cholesterol (Infinity Incorporated, 
Melbourne, Australia) were measured enzymatically at both time points.  
 
Quantification of Aortic Calcium and Atherosclerotic Lesions. Following the intervention 
period, each mouse was sacrificed by CO2 asphyxiation.  The heart, including the proximal aorta, 
was removed, washed in phosphate-buffered saline to remove the blood, placed in freezing 
medium (OCT, Fischer Scientific, Pittsburg, PA), and stored at -80°C until sectioning.  Serial 
sections of heart tissue measuring a thickness of 8μm from the start of the aortic sinus to the 
ascending aorta were sliced, mounted on glass slides (Fischer Scientific, Pittsburg, PA), and 
frozen at  -200C, as described by Daugherty et al200.   
 Calcium in the cryosections was identified by Alizarin red at three specific anatomical 
regions of the proximal aorta each separated by approximately 200 μm , which coincide with the 
start of the aortic sinus, the orifices of the coronary arteries, and the start of the ascending aorta. 
For Alizarin Red staining, slides containing the cryosections were rinsed in 70% ethanol, placed 
in Alizarin red stain for up to 5 minutes, and rinsed in distilled water twice.  Quantification of 
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calcium staining was graded on a scale of 0-4 by blinded investigators.  0 = no staining, 1 = 
weak, non-discrete staining, 2 = light, discrete staining, 3 = intense staining or multiple areas of 
light staining 4 = multiple, intense areas staining201, 202.  Scores were determined by averaging 
the scores of four blinded investigators. 
Additional slides containing cryosections of the same regions of the proximal aorta were 
stained for neutral lipids using Oil Red O to detect and quantify intimal atherosclerotic lesions at 
the same sites.  For Oil Red O staining, slides containing the cryosections were rinsed with 60% 
isopropyl alcohol for 5 min, blotted, and then stained with filtered Oil Red O for 10 minutes and 
blotted once more. Slides were rinsed again with 60% isopropyl alcohol for 2 minutes, blotted, 
rinsed with distilled water, blotted, and then stained with hematoxylin for 10 seconds.  The 
quantification was done using image analysis software (Microsoft Photoshop) and expressed as 
total area of the aorta covered with lipid-filled lesions. 
 
Measurement of Bone Microarchitecture by Micro-Computed Tomography (μCT). The 
right femur was removed from each animal after sacrifice, cleaned of surrounding tissue, and 
stored in ethanol at -20°C.  High resolution images of the femur were acquired using a desktop 
microtomographic imaging system (μCT40; Scanco Medical AG, Basserdorf, Switzerland).  Each 
tissue sample was scanned at 45 keV with an isotropic voxel size of 6 µm, and the resulting two-
dimensional cross-sectional images were shown in gray scale. Scanning began in the  mid-
epiphysis and extended proximally for 3.6 mm (600 CT slices/specimen).  The scans resulted in 
reconstructed 3-D data sets with the µCT Evaluation Program. Trabecular bone was determined 
by specifying regions of interest with the provided software program.   Using these regions of 
interest, the bone volume, trabecular volume and composition were calculated by the program 
using non-destructive three-dimensional reconstruction as described203.   
 
Statistical Analysis. All statistical tests were conducted using SPSS software with two-tailed 
significance set at α = .05.  Plasma variables, atherosclerotic lesions, and bone outcomes were 
assessed using a general linear model univariate two-way ANOVA with diet (casein or soy) and 
activity (sedentary or exercise) as between-subjects factors.  In any analysis, if significant 
interactions were observed, variables were analyzed with post-hoc Tukey’s test.  Main effects 
were only considered when interactions were not significant, as a significant interaction indicates 
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that the effect of one independent variable depends on the value of the other.  The ranked 
calcium scores were analyzed using the Kruskal-Wallis test for nonparametric data.  Data are 
presented as mean ± SEM unless otherwise noted.   
 
Body weight and plasma variables. Body weight and plasma variable values can be found in 
Table 4.2.  There were no interactive or main effects on change in body weight from baseline to 
final measurement.  There was no treatment effect on change in plasma cholesterol, although all 
groups had a decrease in measured plasma cholesterol from baseline to the end of the 
intervention period.  There was no interactive effect on plasma urea, but there was a significant 
diet main effect for the change in plasma urea values (F1,49=0.614; p=0.013), with greater 
reduction of plasma urea in the Soy/Sed and Soy/Ex groups compared to Cas/Sed and Cas/Ex.     
Results 
 
Atherosclerotic Lesion Area and Aortic Calcium. There was no significant effect of diet or 
exercise on atherosclerotic lesion area at the position in the proximal aorta corresponding to the 
cusps of the aortic valves or at the branch point of the coronary arteries (Figure 4.1a).  At the 
position of the proximal aorta corresponding to the start of the ascending aorta, there was a 
significant interaction effect (F1,54=4.945; p<0.05) with the Cas/Ex animals tending to have the 
greatest lesion area at this site. Nonparametric analysis of ranked calcium scores revealed no 
significant differences between groups, although the mean rank for the control group was the 
highest at each of the three aortic sections described above (Figure 4.1b).     
 
Bone Microarchitecture. There was a significant interaction effect of diet and activity 
(F1,51=4.006; p=0.05) on total volume (TV) but not for log-transformed bone volume.  However, 
there were significant main effects of diet (F1,50=4.086; p<0.05) and exercise (F1,50=9.007; 
p=0.004) for log-transformed bone volume (BV) resulting in an overall main effects of diet 
(F1,50=8.596; p<0.01) and exercise (F1,50=10.070; p<0.01) on the total volume to bone volume 
ratio (BV/TV), or relative bone volume (Figure 4.2a).  The Soy/Ex group showed a 61% 
increase in relative bone volume compared to the Cas/Sed animals. There were no interactive 
effects on measures related to bone architecture, but there were several main effects of our 
treatments.  This included a significant main effect of diet (F1,50=13.112; p=0.001)  and activity 
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(F1,50=11.325; p=0.002) on trabecular number, with the Soy/Ex group tending to have the 
greatest number of trabeculae compared to Cas/Sed (Figure 4.2b).  There were also significant 
main effects of diet (F1,50=9.990; p=0.003) and activity (F1,50=5.873; p=0.02) on trabecular 
separation (Figure 4.2c).  Again, the Soy/Ex group tended to have less separation compared to 
Cas/Sed. There were also significant main effects of diet (F1,51=9.950; p=0.003) and exercise 
(F1,51=4.149; p<0.05) on the log transformation of trabecular connective density (Figure 4.2d), 
with a trend for an interaction effect (p=0.089).  In a manner similar to trabecular number and 
separation, the highest connective density was in the Soy/Ex animals compared to Cas/Sed. 
There were no effects of treatment on trabecular thickness (0.0375±0.001, 0.0482±0.001, 
0.0515±0.001, 0.0492±0.001 for Cas/Sed, Soy/Sed, Cas/Ex and Soy/Ex, respectively). 
 
The primary findings in this study were that both a soy protein diet and exercise training 
significantly increased relative bone volume and improved bone microarchitecture in a mouse 
model of disordered lipid metabolism and surgically-induced renal insufficiency .  The effect 
tended to be greatest when these interventions were administered in combination. Although the 
interaction effect was not significant for any of the bone measures (with the exception of total 
volume as a component of relative bone volume, or BV/TV), the Soy/Ex combination group 
tended to have more favorable bone variables when compared to the other treatment groups.  
Furthermore, we found a main effect of diet on the change in plasma urea levels during the 
intervention period, with animals on the soy diet having lower plasma urea levels.  Finally, 
neither soy nor exercise had much effect on the vasculature.  There were no  group differences in 
aortic calcium in any of the 3 proximal aorta sections, and no interactive or main treatment 
effects in atherosclerosis in 2 of the 3 proximal aorta sections.  Surprisingly, we observed an 
interaction effect of diet and exercise on atherosclerotic lesion area in the section of the proximal 
aorta corresponding to the start of the ascending aorta, with the exercise only animals having the 
greatest lesion area.  However, this effect was ameliorated with the combination treatment.  
These data suggest that a combination of a soy-rich diet and endurance exercise training may be 
beneficial for protection of bone health and preservation of renal function in individuals with 
CKD, although the effects in the vasculature remain unclear.   
Discussion 
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Observational studies have linked high soy protein consumption with lower osteoporotic 
fracture risk, but the treatment effect of soy protein on bone density and microstructure remains 
controversial in healthy populations, and even less is known about the effects of soy protein on 
bone health in the context of CKD.  Intake of soy protein has been shown to improve bone 
mineral density while others have shown no effect on a variety of bone parameters, and much 
attention has been focused on the phytoestrogens contained in soy protein.  Furthermore, recent 
research suggests that the efficacy of soy protein on bone depends on the ability of the body to 
convert the soy isoflavone daidzein to equol, a potent estrogenic metabolite.  Only 20-35% of the 
population have been reported to have the ability to metabolize daidzein to equol via intestinal 
microflora204, and this may partially explain the differential responses to soy protein 
interventions in the context of bone health; the effectiveness of equol production in the context 
of kidney disease is not known.  In addition, mice produce equol prolifically when fed diets 
containing soy protein205, and may explain why the efficacy of soy protein is more modest in 
human studies.  In this study, we found a significant main effect of diet not only on relative bone 
volume, but also on bone microstructure including trabecular number, thickness, and density.      
Furthermore, we also found a main effect of activity on the same parameters, with a trend 
toward a greater effect in the combined soy plus exercise group.  Several studies have found a 
synergistic effect of phytoestrogens and exercise on improving bone parameters in 
ovariectomized mice, rats, and premenopausal women (reviewed in 206).  Exercise is known to 
stimulate the estrogen receptor on bone, and this action may contribute to the enhanced bone 
microarchitecture seen in the soy and exercise combination group.  Oh and colleagues have 
suggested soy isoflavone supplementation protects against exercise-induced oxidative stress193, 
which may explain why the benefits demonstrated in this study were more pronounced in the 
combination group compared to exercise training alone.  While many of these animal studies 
used subcutaneous injections of soy isoflavones in doses ranging from 0.4-6.4 mg/day, we have 
demonstrated beneficial effects of intact soy protein on bone health in our uremic mouse model 
using 250 mg of isoflavones/kg diet (per manufacturing specifications, Harlan Teklad, Madison, 
WI) with an effective dose of about 0.625 mg of isoflavones per day.  We believe the distinction 
between soy protein use and isoflavone supplementation to be important, as studies have 
suggested that the benefits of soy may be due to other components of the intact protein in 
addition to the phytoestrogenic effects of soy isoflavones.   
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Most studies have looked at the effects of soy protein on bone loss in women, targeting 
the stages before and after menopause.  However, the metabolic and hormonal conditions and the 
subsequent consequences on bone may be different for an individual with CKD compared to 
healthy pre- or post-menopausal woman and the benefits of soy in pre- and post-menopausal 
women may not translate to this population.  Specifically, CKD patients can experience both 
high- and low-turnover bone disease in response to the metabolic changes induced by declining 
kidney function.  To date, no study has looked at the efficacy of soy protein for bone parameters 
in the context of CKD, either with animal models or in human populations.   Furthermore, soy 
protein may represent a valid therapy  in this population for treating CKD associated bone 
conditions, as studies have shown that soy proteins do not effect glomerular filtration rates or 
post-prandial renal blood flow in the same way that animal proteins do after a high protein 
meal207.  Therefore, with soy protein consumption, CKD patients are able to get the benefits of 
protein without the negative effects on the kidneys that have been reported for animal proteins. 
In addition to the mechanisms listed above, soy protein supplementation may have effects 
on CVD that are specific to CKD.  For example, soy supplementation has been associated with 
reduced oxidized-LDL in hemodialysis patients115, reduced urinary albumin excretion and 
LDL/HDL cholesterol ratio116  in patients with diabetic nephropathy, and preservation of renal 
function in moderate kidney disease116, 117.  In this study we measured plasma urea as a measure 
of the kidney’s ability to metabolize nitrogenous waste; this ability is impaired with renal 
insufficiency and the consequent buildup of urea and other toxins may contribute to the common 
co-morbidities of CKD.  We found a main effect of diet on change in plasma urea levels 
measured at baseline and prior to sacrifice, suggesting that soy protein may be improving uremic 
conditions.  Protein restriction as a means to preserve renal function has been widely practiced 
for many years, but the efficacy of this treatment has recently been called into question208.  As 
individuals with CKD progress to renal failure, the incidence of protein wasting sharply 
increases9 and is associated with low quality of life, low physical functioning, and even 
mortality12.  The high prevalence of protein malnutrition in CKD patients may be due in part to 
the clinical recommendations to restrict protein during moderate to severe renal impairment.  As 
this study suggests, the addition of soy protein in moderate CKD may not have any detrimental 
effects on kidney function and has the potential to slow or prevent the occurrence of protein 
wasting in later stages of CKD.   
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We did not see any improvements in the vasculature, either in atherosclerotic lesion area 
or aortic calcium score, for any of the treatment groups compared to the control animals. In fact, 
we found an interaction effect of diet treatment group and exercise training on atherosclerotic 
lesions at the site of the proximal aorta corresponding to the ascending aorta, with the exercise-
trained animals having significantly higher lesion area compared to the other groups.  Combining 
soy protein diet plus exercise seemed to ameliorate this effect, but the lesion areas in the 
combination group were not significantly different from the control sedentary animals.  Exercise 
training has been shown to reduce CVD risk in individuals with normal kidney function and to 
improve physical function in CKD, but virtually no studies to date have looked at exercise 
training on CVD outcomes in CKD patients, and these studies have focused on patients with 
renal failure (reviewed in 209).  Phan et al showed that pharmacological treatment in an identical 
animal model slowed the progression of uremia-associated atherosclerosis210, while the same 
group found a reduction in atherosclerosis with the antioxidant n-acetylcysteine211, highlighting 
the high burden of oxidative stress in CKD.  However, we did not see such an effect with dietary 
or exercise intervention on aortic atherosclerosis or calcification, and this may be due to the 
severity of the surgical procedure used to create this model of renal insufficiency.  It is possible 
that the deficiency of apoE combined with the high stress of the 5/6 nephrectomy was too severe 
to warrant endurance exercise training as a therapeutic means to reduce uremia-associated CVD 
with this particular model.  Studies on the beneficial effects of exercise on cardiovascular risk in 
humans with varying degrees of kidney function are clearly needed.     
There were several limitations to this study.  First, we feel that the severity of the surgery 
with this model may have prevented the dietary and exercise intervention from having any effect 
in the vasculature.  As these are primarily preventative measures, this may provide a rationale to 
begin such treatments before the development of severe renal impairment.  Additionally, it is not 
known whether the same effects on the vasculature or bone would be seen in male mice, 
accounting for the estrogenic properties of soy isoflavones.  As mentioned earlier, the efficacy of 
soy protein may depend of the ability to metabolize the isoflavone daidzein to equol; all mice are 
equol producers while only a percentage of humans possess this capability.  Therefore, it is 
unclear if these results would be seen in humans with CKD.  Food intake was not measured with 
these animals, so we are not able to determine the effect of food intake on the results of this 
study.  Finally, apo E-/- animals have been shown to have an increase in bone mass compared to 
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wild type mice; renal insufficiency in this model decreases bone volume.  It is not known based 
on this current study if the increase in bone volume would translate to improved fracture risk, or 
if it represents a pathological disorder of bone remodeling; furthermore, without indices of bone 
formation and resorption, we are unable to make these determinations.   
In summary, we found beneficial effects of soy protein and exercise on properties of bone 
and plasma urea in mice with surgically induced renal impairment showing a trend toward a 
stronger effect with a combination approach.  Further research involving individuals with CKD 
is needed to test the efficacy and practicality of these lifestyle interventions on preventing the 
decline in cardiovascular and bone health associated with CKD and perhaps the preservation of 
residual renal function in early stages of the disease.    
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Tables 
Table 4.1:  Composition of Study Diets 
 
 
Selected Components Casein Diet HT TD.06650 Soy Diet HT TD.06653 
Isolated Soy Protein1 0.0 g/kg 200.0 g/kg 
Casein 200.0 g/kg 0.0 g/kg 
Sucrose 150.0 g/kg 150 g/kg 
Corn Starch 371.8 g/kg 368.8 g/kg 
Maltodextrin 120.0 g/kg 120 g/kg 
Cellulose 50.0 g/kg 50.0 g/kg 
Soybean Oil2 60.0 g/kg 60.0 g/kg 
Mineral Mix AIN-93G 35.0 g/kg 35.0 g/kg 
Vitamin Mix AIN-93G 10.0 g/kg 10.0 g/kg 
1Contains 250 mg/kg isoflavones (per manufacturer’s specifications) 
2 Soybean oil does not provide any isoflavones.   
HT= Harlan Teklad 
 
 
 
 
 
 
 
Table 4.2: Body weight, plasma cholesterol, and plasma urea at baseline and final measurement 
for all treatment groups1. 
 Cas/Sed 
(n=16) 
Soy/Sed 
(n=18) 
Cas/Ex 
(n=14) 
Soy/Ex 
(n=12) 
Body Weight:Baseline (g) 17.5±0.8 17.2±0.7 16.9±1.1 17.8±0.8 
Body Weight:Final (g) 21.3±0.7 20.2±0.9 19.2±1.6 21.0±1.1 
Body Weight: Delta 3.8±0.8 3.0±0.8 2.3±1.1 3.2±1.0 
Cholesterol:Baseline (mg/dL) 409.9±25 484.4±25 466.5±22 429.1±15 
Cholesterol:Final (mg/dL) 328.2±14 407.5±18 378.4±19 385.3±12 
Cholesterol:Delta -79±25 -78±33 -105±17 -44±15 
Urea:Baseline (mmol/L) 16.3±0.9 15.9±1.0 15.9±0.7 17.0±0.6 
Urea:Final (mmol/L) 17.0±0.7 14.1±0.6 15.6±0.5 15.3±0.7 
Urea:Delta  0.71±0.9 -1.78±0.8* -0.26±0.5 -0.73±0.5* 
1 Values are presented as mean ± SEM.  * p<0.05 for diet main effect.  Cas/Sed=casien diet, 
sedentary; Soy/Sed=soy diet, sedentary; Cas/Ex=casein diet, exercise trained; Soy/Ex=soy diet, 
exercise trained 
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Figures  
Figure 4.1 
 
 
 
 
 
Figure 4.1: Atherosclerotic lesions and aortic calcium in sections corresponding to the cusp   of 
the aortic valves (Area A), the branch point of the coronary arteries (Area B), and the ascending 
aorta (Area C).  There was a significant interaction between experimental diet treatment and 
exercise training on atherosclerotic lesions at the site corresponding to the ascending aorta (Area 
C) with significantly higher lesion area in Cas/Ex (a).  There was no significant interactive or 
main effects of diet or activity on aortic calcium score (b).  * p<0.05 for an interaction effect at 
this site.  Cas/Sed=casien diet, sedentary (n=16); Soy/Sed=soy diet, sedentary (n=18); 
Cas/Ex=casein diet, exercise trained (n=14); Soy/Ex=soy diet, exercise trained (n=12). 
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Figure 4.2 
 
 
Figure 4.2:  Relative bone volume and bone microstructure in response to dietary and activity 
intervention.  There were no interactive effects for diet and activity on any variable measured.  
However, there was  significant main effects of soy protein diet (* p<0.05) and exercise training 
(§ p<0.05) on relative bone volume (a), trabecular number (b), trabecular separation (c), and 
connective density (d).  Cas/Sed=casien diet, sedentary (n=16); Soy/Sed=soy diet, sedentary 
(n=18); Cas/Ex=casein diet, exercise trained (n=14); Soy/Ex=soy diet, exercise trained (n=12). 
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CHAPTER 5 
 
FACTORS RELATED TO CHRONIC KIDNEY DISEASE CO-MORBIDITIES 
 
Chronic kidney disease (CKD) patients receiving hemodialysis treatment (CKD stage 5) 
suffer from a variety of co-morbid diseases, many of which may be mechanistically linked and 
are influenced by a chronic inflammatory state.  Cardiovascular disease (CVD) is the leading 
cause of death in individuals with CKD and cardiovascular events are 10 to 30 times greater in 
CKD than in age- and sex-matched subjects in the general population14.  Traditional CVD risk 
factors, including elevated cholesterol, hypertension, age, and gender, do not fully explain the 
elevated CVD mortality, and it may be partially attributed to novel cardiovascular risk factors, 
including excessive inflammation and oxidative stress and abnormalities in mineral metabolism 
that contribute to increases in arterial stiffness, intima-media thickness, and vascular 
calcification.   
Introduction 
Dialysis patients also have significantly elevated rates of osteoporosis189 along with a 
specific metabolic bone remodeling disorder known as chronic kidney disease-mineral bone 
disease (CKD-MBD) 35 leading to increased fracture risk, mortality, and morbidity190.  
Furthermore, there is emerging evidence that the loss of mineral from bone and the stiffening of 
the vasculature are mechanistically linked.  In response to a variety of stimuli, vascular smooth 
muscle cells (VSMC) are stimulated to differentiate into an osteoblast-like phenotype41 capable 
of producing a bone-like matrix and mineralizing in the presence of calcium and phosphorus, 
thereby increasing the stiffness of the vessel.  This process appears to be regulated by proteins, 
including fetuin-a and alkaline phosphatase (ALP), secreted from VSMC and endothelial cells 
that either promote or inhibit calcium and phosphate precipitation and the formation of 
hydroxyapatite crystals43.  The expression of these proteins in vascular cells and bone may be 
mediated in part by inflammation51 and malnutrition55   
In fact, malnutrition-inflammation complex is very common in dialysis patients for 
reasons including poor nutrient intake, protein losses during dialysis, and elevated whole body 
and skeletal muscle protein catabolism that occurs during dialysis (reviewed in10).  Protein 
malnutrition is associated with a loss of lean mass and functional declines in hemodialysis 
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patients212 that reduce physical activity levels and exacerbates co-morbidities including CVD and 
bone disorders.    
Beyond the role of decreased physical activity levels, it is well-established that 
inflammation contributes directly to the development and progression of other CKD co-
morbidities.  Evidence suggests inflammatory mediators are associated with cardiovascular 
complications in CKD patients64, and recently research has begun to focus on the impact of 
epicardial adipose tissue, a visceral fat depot surrounding the heart, on CVD risk due to its role 
as a cytokine-secreting tissue.   Inflammation is also is implicated in the development of renal 
bone disease56, 72, 73.  Interleukin-6 (IL-6), expressed by both inflammatory cells and osteoclasts, 
has been shown to promote bone resorption in patients with renal osteodystrophy73, and also has 
been implicated in high bone turnover in multiple myeloma74 and estrogen deficiency75.  Taken 
together, these findings suggest that the chronic inflammation associated with advanced CKD 
promotes the development and progression of many of the co-morbidities that reduce the QOL 
and increase mortality rates in this population. 
Patients receiving hemodialysis therapy are at greater risk for a large number of these co-
morbities compared to age- and sex- matched controls; this study aims to determine predictors of 
these important functional outcomes from a comprehensive set of variables including measures 
of cardiovascular risk, bone health, body composition, markers of inflammation, clinically 
relevant plasma variables, functional fitness, muscle strength and quality of life in hemodialysis 
patients.  We hypothesize many of these factors are interrelated and also strongly influenced by 
inflammation.    
 
Subject Recruitment, Screening, and Selection.  Individuals with CKD receiving hemodialysis 
treatment at the Champaign-Urbana Dialysis Center in Champaign, IL and the Oak Park Dialysis 
Clinic in Oak Park, IL were recruited at their respective clinics.  Patients that met the following 
criteria were enrolled in the study:  1) Subjects must receive hemodialysis treatment at least 3 
days per week. 2) Subjects must be ≥ 30 years of age. 3) Subjects greater than 400lbs were 
excluded due to weight limitations on the dual x-ray absorptiometry (DXA) table.  4)  Patients 
with congestive heart failure or chronic obstructive pulmonary disorder were excluded 5) 
Subjects must have been receiving dialysis treatment for ≥ 3 months as disruption in metabolic 
Materials and Methods 
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factors is related to duration of dialysis treatment.  A Health and Medical History Questionnaire 
was administered during the screening, and informed consent was obtained from each 
participant.  All research protocols were conducted with the approval of the University of Illinois 
Institutional Review Board.   
Sixty dialysis patients completed testing and were included in this cross-sectional 
analysis.  With the exception of the blood chemistries, all testing and measurement were 
performed 18-24 hours after the most recent dialysis session on a non-treatment day.  Blood 
collections were not performed on Mondays or Tuesdays to control for the extra day between 
treatments that occurs during the weekend.  For example, blood would not be drawn for a 
Monday/Wednesday/Friday scheduled patient on Monday as they would not have dialyzed since 
Friday (two day lapse).  For a Tuesday/Thursday/Saturday scheduled patient, blood would not be 
drawn during their treatment on Tuesday for the same reason.  All testing was done on identical 
equipment at both sites; all blood chemistries and data analysis were performed in Champaign, 
IL. 
 
Blood Chemistry.  Non-fasted blood samples were drawn from patients at the dialysis clinic 
immediately after initiation of dialysis treatment during each participant’s regularly scheduled 
treatment.  Plasma was collected by centrifugation and divided into 1ml aliquots and stored at -
80oC until analyzed.  Circulating levels of inflammatory markers interleukin-6 and 
polymorphonuclear elastase protease inhibitor complex were measured using commercially 
available ELISA kits (R&D Biosystems, Minneapolis, MN; EMD Chemicals Darmstadt, 
Germany).  In addition, blood collected at the dialysis clinic during normally scheduled blood 
draws was assessed for standard clinical lab parameters (plasma albumin, phosphorus, calcium, 
etc) by a Spectra Laboratories, a renal specific laboratory service provider (Rockleigh, NJ).    
 
Carotid Artery Compliance. A combination of ultrasound imaging of the common carotid 
artery with simultaneous arterial tonometry of the contralateral carotid artery (for estimation of 
carotid blood pressure) was used to determine carotid arterial compliance. Carotid ultrasound 
images were obtained from the common carotid artery, 1-2 cm proximal to the carotid 
bifurcation using a 7-13 MHz linear array transducer with a sampling rate of 1000 Hz. B-Mode 
and M-mode images were obtained and displayed simultaneously and automated wall tracking 
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software was used to detect changes in lumen size as described above. The electronic calipers 
were applied to the arterial wall using the B-mode image and wall tracking was conducted using 
the M-mode image in real time. Changes in lumen size between systole and diastole were 
recorded for 12 seconds and an ensemble average beat were constructed from which 
measurements of arterial compliance and stiffness were calculated. Arterial compliance (AC) and 
the beta stiffness index (β) were calculated together with lumen size in systole and diastole using 
the calculations shown below:  
 
-AC (arterial compliance: index of blood vessel compliance) = π (Ds ×Ds - Dd×Dd) / [4 (Ps – 
Pd)]  
-β (stiffness parameter: index of arterial stiffness) = In (Ps / Pd) / [(Ds – Dd) / Dd]  
 
Brachial blood pressure was obtained using standard methods following a 10 minute rest period. 
Pressures were corrected for hold down pressure. 
 
Epicardial Fat Thickness.  The thickness of the epicardial fat layer was measured by 
transthoracic two-dimensional guided echocardiogram, as previously described170.  In brief, 
standard parasternal and apical views were obtained with subjects in the left lateral decubitus 
position. Epicardial fat was  identified as the echo-free space between the outer wall of the 
myocardium and the visceral layer of pericardium and its thickness was measured 
perpendicularly on the free wall of the right ventricle at end systole in three cardiac cycles 170. 
Maximum epicardial fat thickness was measured at the point on the free wall of the right 
ventricle along the midline of the ultrasound beam, perpendicular to the aorta annulus. The 
average value of 3 cardiac cycles for each echocardiographic view was considered as the 
epicardial fat thickness. 
 
 Bone Mineral Density and Body Composition. Bone mineral density (BMD) and whole-body 
soft tissue composition were measured by DXA using a Hologic QDR 4500A bone densitometer 
(software version 11.2, Bedford, Massachusetts) from scans of the whole body, lumbar spine and 
proximal femur.  All scans were analyzed and quality-controlled by the same two technicians.  
Short and long-term accuracy of the densitometer was verified by scanning a manufacturer’s 
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hydroxyapatite spine phantom of a known density. Precision for DXA measurements of interest 
are ~1.0 – 2.0% in our laboratory.  Mineral free lean mass (MFLM) was calculated from DXA 
values as lean mass of selected compartment – bone mineral content of selected compartment 
(whole body, trunk, leg, etc).  
 
Anthropometric Measures. Barefoot standing height was measured to the nearest 0.1 cm with a 
stadiometer and body weight was measured on a balance scale with shoes and superfluous outer 
garments removed. Waist circumference was measured as the minimum circumference between 
the top of the iliac crest and the distal end of the rib cage along the midaxillary line. All 
measurements were taken in duplicate and averaged. 
 
Functional Fitness Testing.  Subjects underwent the following functional fitness assessments 1) 
Chair Stand Test where subjects were asked to stand up from a seated position as many times as 
possible within 30 seconds 2)  Arm Curl Test in which subjects were asked to complete as many 
arm curls as possible during 30 seconds using either a 5 pound dumbbell for females, an 8 pound 
dumbbell for males 3) Chair Sit and Reach Test that asked subjects to reach forward with both 
arms to try and touch their extended leg to assess flexibility, 4) Back Scratch Test where subjects 
tried to touch their middle fingers behind their back to assess upper body flexibility, 5) 8 Foot 
Up-and-Go Test in which subjects walked around a cone placed 8 feet away from their chair and 
back again during a timed trial, and 6) Stair Test in which subjects walked up and down a flight 
of stairs during a timed trial.  In addition, Gait Speed was determined by averaging the triplicate 
of time needed to walk a 10-meter course at a normal, natural pace.    
 
Shuttle Walk Test.  Participants underwent a shuttle walk test to assess physical performance in 
which they walk back and forth continuously on a 10 meter course. The walking was paced by 
beeps which were programmed to have participants maintain each speed for one minute and then 
the pace was increased. The speeds increased so that in each successive minute the speeds were 
as follows: 1.12, 1.54, 1.88, 2.26, 2.64, 3.02, 3.4, 3.78, 4.16, 4.54, 4.92, and 5.3 miles per hour. 
The patient continued until they failed to achieve the distance to the end of the course by the 
beep and the total time was calculated. 
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 Measures of physical performance such as this shuttle walk test are frequently used to 
assess function in older and diseased people instead of more objective measures of aerobic 
capacity such as VO2max testing.  This is due to functional limitations like muscle weakness and 
shortness of breath that prevent these individuals from achieving standard criteria used in 
assessment of these more objective tests136.  This shuttle walk test is well established as a part of 
the guidelines for assessment of fitness in patients with chronic pulmonary disease213, and is 
often preferred to the six minute walk test because it is paced, and therefore more objective.  
 
Muscle strength.  Bilateral quadriceps femoris and hamstring muscle strength were evaluated 
using isokinetic testing modes.  Following dynamometer calibration, knee extension and flexion 
isokinetic muscle torque were evaluated at a speed of 60 degrees per second on a Biodex System 
3 dynamometer.  The axis of rotation of the machine was aligned with the lateral epicondyle of 
the femur and the calf pad was positioned halfway between the lateral malleolus of the fibula and 
lateral epicondyle of the femur, and securely attached to the subject using straps.  Participants 
performed two sets of 6 repetitions, with a 3-minute rest between sets, and the best effort was 
used for analysis.  
 
Quality of Life Assessment.  Physical and mental health status was measured by the 12-Item 
Short Form Survey derived from the Medical Outcomes 36-item Short Form Survey214. Global 
QOL was measured by the Satisfaction with Life Scale215, 216. This measure is a cognitive 
judgment of one's life taken as a whole, and is usually thought to involve comparing one's life 
against some standard. These scales have been shown to be reliable and valid indices of 
components of subjective well-being.  The scales used in this analysis included the Basic Lower 
Extremity Function Scale (BLEF) to assess self-reported function in the lower extremities, self-
reported Mental Health Score (MHS), Total Disability Score (TDS) as a composite of several 
disability-related subscales, and Godin Weekly Leisure Activity Score (GWLAS) as a measure 
of leisure-time physical activity for study participants.    
 
Diet assessment.  Participants were given two 24- hour food recall interview with a trained 
researcher on consecutive days to account for variations in eating patterns associated with 
dialysis treatment.  The interview was conducted using a modified version of the United States 
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Department of Agriculture 5-pass method: the first pass asked for the patients to recall 
everything they ate during the previous 24-hours, the second pass probed for foods that may have 
been forgotten including beverages, snacks, and condiments, the third pass included prompts for 
portion sizes and food amounts, the fourth pass asked for details about the food including brand 
names, and the fifth pass consisted of a final review of the record.  The records were analyzed for 
macronutrient composition and other dietary variables using Nutritionist Pro Data Analysis 
Software (Stafford, TX).  
 
Statistical Analysis. All data are presented as mean ± SEM with a significance level set at 
p<0.05.  Data records were analyzed by t-test for differences between treatment and non-
treatment days.  Multiple linear regression analysis was used to determine predictors of 
functional outcomes of interest.  For all linear regression analysis, gender, diabetes status, and 
smoking were coded as follows:  male=1, female=2; diabetes=1, no diabetes=2; smoker=1, 
nonsmoker=2.    All analyses were conducted using SPSS v.17 (Chicago, IL).   
 
Patient Characteristics. Sixty patients undergoing dialysis treatment enrolled in this study and 
completed testing protocols.  Subject demographics can be found in Table 5.1.  The percentage 
of male participants was 56.7%, the mean BMI was 32.1±1.0 (obese category), and the mean 
time on dialysis treatment was 59.8±6.4 months.   
Results 
Plasma variables are listed in Table 5.2.  Measured levels of plasma IL-6 were 8.42±1.2 
pg/mL and did not differ between genders.  Plasma phosphorus, intact parathyroid hormone, 
blood urea nitrogen (BUN) and creatinine levels were elevated in this patient group compared to 
desirable reference ranges for dialysis patients according to the National Kidney Foundation 
Chronic Kidney Disease Outcomes Quality Initiative (NKF KDOQI).  While plasma iron and 
tranferrin saturation levels were within normal range, ferritin levels were extremely elevated in 
both males and females and total iron binding capacity was lower than recommended clinical 
values.  Additionally, mean hemoglobin and hematocrit levels were low, suggesting anemia of 
renal insufficiency.  Mean plasma albumin levels of 3.94±.04 indicate normal nutritional status.   
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Diet Intake. Twenty-four hour dietary recalls were analyzed to assess nutrient intake on both 
dialysis treatment and non-dialysis treatment days.  Values for selected nutrients measured are 
reported in Table 5.3.  On dialysis days, patients reported intake of 199 fewer total calories 
(p<0.05), 32.6 fewer grams of carbohydrate (p<0.05), 80.7 fewer mg of cholesterol (p<0.05), 2.9 
fewer milligrams of iron (p<0.05), and 167 fewer mg of phosphorus.  There were no differences 
between dialysis and non-dialysis day for fat grams, percent of calories from fat, protein grams, 
or protein grams per kilogram body weight, and percentage of calories from protein was 2.7% 
higher on dialysis treatment days (p<0.05).  Mean protein intake per kilogram body weight was 
0.77 on dialysis days and 0.80 on non-treatment days.  Multiple linear regression analysis did not 
produce any significant predictors of protein or calorie intake when gender, age, weight, mental 
health score, and total disability score were included in the model. 
 
Factors Related to Functional Outcomes. We used multiple linear regression analysis to 
examine variables related to fitness and strength, body composition, and CVD risk.  Results from 
multiple linear regression analysis are displayed in Table 5.4. 
Measures of fitness and strength:  Variables included in the model to determine predictors of 
fitness and strength were gender, age, diabetes status, albumin, leg mineral-free lean mass, Basic 
Lower Extremity Function Scale (BLEF), and plasma IL-6 levels.  Female gender, presence of 
diabetes, and lower reported BLEF scores predicted poorer performance on the Walk Test 
(shorter time) and Gait Speed (longer time).  Gender was the only predictor of peak torque of 
extension as a measure of muscle strength, although the overall model was not significant for 
peak torque.        
Measures of Bone Density:  Gender significantly predicted whole body bone mineral density in a 
model that included gender, weight, age, plasma IL-6, plasma alkaline phosphatase (ALP), and 
daily average calcium intake.  Gender, weight, and ALP predicted total hip BMD in the same 
model, with female gender, low weight, and high ALP associated with lower hip BMD. 
Measures of Body Composition:  Gender and weight were the only predictors of both whole 
body lean mass and whole body percent fat, with adjusted R2 values of 0.784 and 0.728, 
respectively.  Female gender and lower weight predicted lower lean mass and higher percent fat.  
The total model included gender, weight, age, diabetes status, IL-6, albumin, and average daily 
protein intake. 
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Measures of cardiovascular risk:
 
  Epicardial fat thickness was predicted by whole body percent 
fat and plasma IL-6 levels, although the overall model did not reach statistical significance 
(p=0.076).  The full model included gender, age, smoking, diabetes, albumin, IL-6, Godin 
Weekly Leisure Activity Score, whole body % fat, and average saturated fatty acid intake (SFA).  
We also found gender, age, smoking, whole body BMD, SFA intake and intima-media thickness 
predicted arterial β-stiffness in the same model used for epicardial fat thickness plus IMT and 
plasma calcium phosphorus product.  Epicardial fat thickness was also positively correlated with 
plasma polymorphonuclear elastase protease inhibitor complex, a novel marker of inflammation 
in dialysis patients (r=0.494, p=<0.05) (Figure 5.1).     
Through this cross-sectional analysis, we found multiple aspects of chronic kidney 
disease that are interrelated, supporting the idea of the cycle of disease and disability 
characteristic of hemodialysis patients.  This study was notable for its comprehensive inclusion 
of functional outcomes variables associated with hemodialysis treatment in an effort to 
characterize relationships among these factors, and possibly provide information on how best to 
intervene to improve health outcomes in this extremely sick population.  We were able to 
consider cardiovascular disease risk, bone health, functional fitness capacity, muscle strength, 
body composition, dietary intake, clinically significant plasma variables, and demographics in 60 
patients undergoing regular hemodialysis therapy in Champaign, IL (n=45) and Oak Park, IL 
(n=15).  Patient demographics indicate a very similar percentage of male patients and incidence 
of diabetes to the national and state averages for dialysis patients.  Patients in this study were 
slightly younger than average dialysis patients, with a much higher percentage of African-
Americans.  
Discussion 
 We found elevated plasma phosphorus, iPTH, and creatinine levels which is 
characteristic of dialysis patients.  In addition, we were able to assess several measures of iron 
status in this analysis.  Over 95% of our participants were receiving recombinant erythropoietin 
(EPO), which is produced by healthy kidneys to stimulate red blood cell production.  Anemia of 
renal insufficiency from lack of EPO and true iron-deficiency anemia are very prevalent in 
dialysis patients; however, many also suffer from a distinct type of anemia termed anemia of 
chronic disease induced by chronically elevated levels of inflammation.  We found high levels of 
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ferritin, an acute phase protein, along with low total iron binding capacity (TIBC) in the presence 
of normal iron and transferrin saturation, indicative of anemia of inflammation rather than true 
iron deficiency anemia.  The disregulation of iron that occurs with anemia of chronic disease 
seems to be driven particularly by the cytokine IL-6217;  in response to increasing IL-6 levels, the 
liver produces increased amounts of the hormone hepcidin which prevents the release of stored 
iron.  The high levels of IL-6 along with elevated ferritin and low/normal TIBC in this study 
suggest inflammation may be contributing to anemia and poor nutrition status in these 
individuals.  In fact, some researchers are questioning the usefulness of ferritin as a marker of 
iron stores, suggesting instead that moderate hyperferritinemia is indicative of inflammation, 
infection, and malnutrition rather than an indicator of iron status218. 
 We found dialysis patients intake significantly fewer calories (~200kcal) on dialysis days 
compared to non-dialysis days, along with lower amounts of carbohydrates, cholesterol, and iron.  
The National Institutes of Health Hemodialysis Study Group reported significantly lower total 
energy intake as well as lower protein intake on dialysis days compared to non-treatment days in 
a cross-sectional analysis of nearly 2,000 dialysis patients in 15 clinical centers nationwide219.  
However, the average amount of protein reported as consumed in this study was 0.79 grams 
protein/kilogram body weight.  Even though we did not find any differences between treatment 
and non-treatment days, this suggests these patients are getting far below the recommended 
protein intake of 1.2 grams/kilogram body weight.   
Decreased carbohydrate intake in this group accounted for about 120 fewer calories on 
dialysis days, suggesting other macronutrients may have been under-consumed as well, although 
these levels were not significant.  Voluntary suppression of nutrient intake, typically total 
calories and protein, is commonly reported in dialysis patients with about 1/3 of patients 
classified as having CKD related anorexia220.  Although the exact mechanism of appetite 
suppression is unknown, several studies have suggested the uremia-induced accumulation of 
inflammatory cytokines61, 221, 222 may play a role in the voluntary suppression of nutrient intake 
and loss of appetite associated with dialysis treatment.  However, we did not find inflammation 
to be predictive of protein or calorie intake in this study and larger studies are needed to 
determine the relationship between these variables. 
Using regression analysis, we found significant associations between several functional 
measures and other outcomes of interest.  For the Walk Test and Gait Speed, we found gender 
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and diabetes status predicted performance on these assessments, along with the self-reported 
BLEF.  Leg lean mass was not a significant predictor, although this may be due in part to the 
negative correlation between female gender and lower lean body mass.  Studies have suggested 
that females have lower physical activity levels than their male dialysis counterparts223, and that 
this normal daily physical activity is important for maintenance of normal walk speed and ability 
to walk224.  Indeed, we found a negative correlation with gender and GWLAS, although this 
measure is not a comprehensive scale of physical activity so this variable was not included in the 
model.  Simple t-test analysis of males versus females and diabetics versus non-diabetics showed 
that females performed worse on 4 of the 6 measures of functional fitness, 12 of the 19 quality of 
life measures, and all 4 measures of muscle strength compared to males, while diabetics 
performed worse on 4 of 6 functional measures, 14 of the 19 quality of life measures, and none 
of the muscle strength measures compared to non-diabetics.   
Furthermore, female gender significantly predicted lower whole body bone mineral 
density, lower total hip bone mineral density, lower lean body mass, and higher percent whole 
body fat, even when other correlated factors were considered in the model.  Although it was not 
possible to model all of these outcome variables, these data indicate gender, body composition, 
functional fitness, and quality of life are interrelated in this population, supporting the idea of a 
cycle of disease and disability in this population.  Surprisingly, age was not a significant 
predictor in any of these outcomes suggesting that other factors such as gender-associated 
changes in hormones may be contributing to an increased risk of disease and disability in female 
dialysis patients.  In addition to gender and weight, we identified increased alkaline phosphatase 
as a predictor of low hip bone mineral density;  a recent study by Park and colleages225 suggests 
hemodialysis modifies the traditional risk factors for low bone density found in the general 
population, and that identification of dialysis-specific factors related to renal osteodystrophy 
such as ALP are needed.  Other studies suggest that ALP contributes to increase cardiovascular 
risk and mortality in this population226, 227, and targeting the levels of ALP in this population may 
modify both bone health and cardiovascular disease risk simultaneously.         
Although female gender predicted poorer outcome for fitness, body composition, and 
strength, we found female gender was inversely related to arterial stiffness, suggesting a possible 
protective effect on the vasculature.  The detrimental effects of smoking and increasing age on 
arterial stiffening is well known, and indeed we found smoking and age to be predictors of 
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arterial stiffness along with gender, saturated fat intake, and intima-media thickness.  We found 
that higher whole body bone density was predictive of higher arterial stiffness although the 
opposite has been demonstrated in other clinical populations228.  Aoki and colleagues studied the 
relationship between vascular calcification, aortic stiffness, and bone mineral density in dialysis 
patients, reporting associations between bone density and calcification and stiffness and 
calcification, but neglected to report any relationship between stiffness and BMD in this 
population229.  CKD-MBD can include both high- and low-turnover bone disease, and DXA 
measurements are limited to bone mineral content and density without a report of turnover.  
Therefore, the relationship between arterial stiffness and bone density as measured by DXA is 
unclear and warrants further investigation.   
We also found that higher IL-6 levels predicted higher epicardial fat thickness; 
polymorphonuclear elastase-protease inhibitor complex (PMN-Elastase PI), a novel marker of 
inflammation in dialysis patients230, also was positively correlated with epicardial fat thickness.  
However, this marker was only measured in a small subset of study participants and was 
therefore not included in the linear regression model.  However, these data suggest that 
inflammation contributes to epicardial fat thickness in dialysis patients, as shown by a very 
recent study by Turkmen and colleagues reporting increased epicardial fat thickness as the 
presence and number of components of the malnutrition-inflammation, 
atherosclerosis/calcification syndrome increased in dialysis patients231.   
 We were able to confirm several well-known predictors of CKD co-morbidities as well as 
identify some novel predictors of functional outcomes including ALP and IL-6.  We also showed 
a positive association of another inflammatory marker, PMN elastase-PI complex, with 
epicardial fat thickness which suggests that the inflammation may be both cause and 
consequence of the co-morbid conditions of hemodialysis treatment.  Understanding the complex 
relationship between cardiovascular complications, renal bone disorders, and factors that 
contribute to their development including muscle strength and body composition will enable the 
development of appropriate therapeutic targets to improve the health and quality of life of 
hemodialysis patients.         
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Tables 
 
Table 5.1:  Subject Characteristics 
 
Demographics  Total (n=60) 
Gender (Male) 56.7% (n=34) 
Diabetes Status (Diabetic) 46.7% (n=28) 
Smoking Status (Smoker) 31.7% (n=19) 
Age (years) 53.91±1.6 
BMI (kg/m2) 32.09±1.0 
Time on Dialysis (months) 59.8±6.4 
Race/Ethnicity 71.7% African-American (n=43) 
25% White (n=15) 
3.3% Hispanic (n=2) 
Etiology of Kidney Failure  
Hypertension 52% (n=31) 
Diabetes with renal manifestations, Type 1 3% (n=2) 
Diabetes with renal manifestations, Type 2 25% (n=15) 
Polycystic Kidney Disease 5% (n=3) 
Nephritis/Nephropathy 10% (n=6) 
Unknown/Other 5% (n=3) 
Total 100% (n=60) 
When appropriate, data are presented as mean ±SEM.   
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Table 5.2:  Mean values of reported plasma values compared to desirable reference ranges 
 
Plasma Variables Mean Values Reference Range (NKF KDOQI) 
Interleukin-6 (pg/mL) 8.4±1.2 Normal ~1.0 
Bicarbonate (mEq/L) 25±0.4 22-29 
Phosphorus (mg/dL) 6.0±0.2 2.6-4.5 
ALP (U/L) 115±14 M, 94±8 F 40-129 M, 35-104 F 
IntactPTH (pg/mL) 428±55 14-72 
Potassium (mEq/L) 4.8±0.1 3.5-5.1 
Calcium (mg/dL) 9.0±0.1 8.4-10.2 
 CaxP 54±2 0-54 
Albumin (g/dL) 4.0±.04 3.5-5.2 
TransSat (%) 38±2 22-55 
Iron 85±5 M, 76±8 F 45-160 M, 30-160 F 
TIBC (mcg/dL) 217±4 228-420 
Ferritin (ng/mL) 894±92 M, 888±122 F 22-332 M, 10-291 F 
Hemoglobin (g/dL) 13.1±1.4 14.0-18.0 
Hematocrit (%) 36.3±0.6 42.0-52.0 
BUN (mg/dL) 53±2 6-19 
Creatinine (mg/dL) 10.2±0.4 M, 11.8±2.9 F 0.5-1.2 M, 0.4-1.1 F 
BUN_Creat (calculated) 6.2±.40 (no reference provided) 
BUNPost (mg/dL) 15±0.9 6-19 
URR (calculated) 73±1.2 65-80 
Data are presented as mean ± SEM.  Sixty (60) patients were included in this analysis.  
ALP=alkaline phosphatase, PTH=parathyroid hormone, CaxP=Calcium Phosphorus product, 
TransSat=transferrin saturation, TIBC=total iron binding capacity, BUN=blood urea nitrogen, 
BUN_Creat=blood urea nitrogen to creatinine ratio, URR=urea reduction ratio  
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Table 5.3:  Comparison of selected nutrient intake on dialysis and non-dialysis days 
 
 Mean Dialysis-Mean Non-Dialysis p-value 
Calcium (mg) -100±67 0.14 
Calories (kcal) -199±96 0.04 
Calories (kcal)/Body Weight (kg) -2.0±1.1 0.07 
Calories (kcal)/Lean Mass (g) -0.004±0.002 0.05 
Carbohydrate (g) -32.6±15.0 0.04 
Carbohydrate (%) -3.02±2.8 0.29 
Cholesterol (mg) -80.7±32.1 0.02 
Fat (g) -6.41±5.5 0.25 
Fat (%) 0.25±2.3 0.91 
Iron (mg) -2.9±1.4 0.04 
Fiber (g) -0.6±1.2 0.63 
Sodium (mg) -359±290 0.22 
Phosphorus (mg) -167±89 0.07 
Protein (g)/Body Weight (kg) -0.032±0.065 0.62 
Protein (g) -1.8±5.7 0.76 
Protein (g)/Lean Mass (g) -0.00004±0.000 0.70 
Protein (%) 2.73±1.2 0.03 
Vitamin A -160±122 0.19 
Vitamin C -7.4±14.3 0.61 
Data presented are changes in mean ± SEM. p<0.05 is considered significant. 
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Table 5.4:  Multiple Linear Regression Analysis to identify predictors of functional outcomes 
 
 Walk Test R2=0.485, p<0.001 
 t p B 
Gender -2.72 0.011 -102.4 
Diabetes 2.45 0.021 69.3 
BLEF 2.03 0.053 8.09 
 Walk Speed R2=0.492, p<0.001 
 T p B 
Gender 3.32 0.003 4.69 
Diabetes -2.13 0.043 -2.23 
BLEF -2.31 0.029 -0.35 
 Peak Torque 
Extension 
R2=0.112, 
p=0.196 
 t p B 
Gender -2.42 0.024 -54.0 
Variables included in model:  Gender, Age, Diabetes Status, Albumin, Leg Mineral-Free Lean 
Mass, Basic Lower Extremity Function scale, Plasma IL-6  
 
 Whole Body 
BMD 
R2=0.443, 
p<0.05 
 T p B 
Gender -3.12 0.009 -0.14 
 Total Hip BMD R2=0.462, 
p<0.05 
 T P B 
Gender -2.02 0.066 -0.147 
Weight 2.96 0.012 0.005 
ALP -2.60 0.023 -0.001 
Variables included in model:  Gender, Weight, Age, Plasma IL-6, Plasma Alkaline Phosphatase, 
Average Daily Calcium Intake 
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Table 5.4, continued:  Multiple Linear Regression Analysis to identify predictors of functional  
  outcomes 
 
 Whole Body 
Lean Mass 
R2=0.784, 
p<0.001 
Variable T p B 
Gender -5.54 <0.001 -13837 
Weight 7.56 <0.001 341 
 Whole Body % 
Fat 
R2=0.728, 
p<0.001 
Variable T p B 
Gender 5.86 <0.001 14.7 
Weight 7.17 <0.001 0.324 
Variables included in model:  Gender, Weight, Age, Diabetes, Plasma IL-6, Albumin, Average 
Daily Protein Intake 
 
 
 Epicardial Fat 
Thickness 
R2=0.317, 
p=0.076 
Variable t p B 
IL-6 2.17 0.047 0.344 
WB % Fat 2.91 0.011 0.201 
    
 Beta Stiffness R2=0.662, 
p<0.05 
Variable t P B 
Gender 3.59 0.007 6.25 
Age 2.88 0.02 0.149 
Smoking -2.83 0.022 -4.02 
WbBMD 2.33 0.048 26.8 
SFA Intake 2.33 0.048 0.148 
IMT 2.82 0.023 0.234 
Variables included in the model:  Gender, Age, Smoking, Diabetes, Albumin, IL-6, Godin 
Weekly Leisure Activity Score, WB % Fat, SFA Intake, Calcium Phosphorus Product (Beta 
stiffness only), Intima-media thickness (Beta stiffness only) 
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Figures 
Figure 5.1 
 
 
 
Figure 5.1:  Association of Epicardial Fat Thickness and Plasma PMN Elastase PI-Complex 
(n=23).  We found a significant positive association of epicardial fat thickness and levels of the 
inflammatory marker PMN Elastase PI-Complex (r=0.494, p<0.05).  
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CHAPTER 6 
 
ACUTE EFFECTS OF INTRADIALYTIC PROTEIN SUPPLEMENTATION 
 
Chronic kidney disease (CKD) is a progressive inflammatory disorder that affects 
approximately 13% of adults in the U.S, and the prevalence is increasing rapidly1.  Advanced 
CKD requiring dialysis treatment is associated with a variety of metabolic disturbances that 
increase morbidity and mortality; in addition, protein malnutrition, muscle wasting, bone 
disorders, and cardiovascular complications are especially common, and these co-morbidities 
greatly reduce physical function and quality of life in dialysis patients. Furthermore, 2/3 of 
patients die within 5 years of initiation of long-term dialysis treatment, mostly of cardiovascular 
disease (CVD)3, and survival has not increased substantially in the past two decades4. New 
therapeutic approaches are needed to address the many co-morbid conditions associated with 
advanced kidney disease. 
Introduction 
Although dialysis treatment procedures and protocols have improved over the years, 
mortality rates remain elevated in dialysis patients, and many believe protein-energy malnutrition 
and elevated inflammation are one of the primary reasons for this effect.  Protein-energy 
malnutrition (PEM) is very common in dialysis patients, with the incidence rate ranging from 
25% to 75% in different studies6-9. There are a variety of reasons for this, including poor nutrient 
intake, physical illnesses affecting gastrointestinal function, protein losses during dialysis, and 
elevated whole body and skeletal muscle protein catabolism that occurs primarily during 
dialysis10. Furthermore, PEM and inflammation tend to occur concurrently in dialysis patients, 
giving rise to the term malnutrition-inflammation complex or syndrome.   
Inflammation may also be contributing to PEM by inducing appetite suppression, as high 
circulating levels of inflammatory cytokines has been shown to increase anorexia in dialysis 
patients222.  This voluntary decrease in nutrient intake further exacerbates the malnutrition 
inflammation complex syndrome, leading to more inflammation and further declines in 
nutritional status.  In particular, IL-6 seems particularly important as a marker and mediator of 
dialysis-associated inflammation. Tripepi and colleagues indicate IL-6, compared to several 
other inflammatory cytokines, adds the greatest predictive power with regards to all-cause and 
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cardiovascular mortality in the context of traditional and non-traditional risk factors for dialysis 
patients232.  Furthermore, the dialysis procedure induces an acute increase of IL-6233 during the 
course of a single treatment that persists into the post-dialysis phase, and other inflammatory 
markers may be transiently elevated in conjunction with dialysis treatment230.   
Anemia of chronic disease, often termed anemia of chronic inflammation, occurs in 
dialysis patients due to chronic immune activation, infection, and inflammation234.  Individuals 
with advanced CKD very commonly suffer from another type of anemia called anemia of renal 
insufficiency due to the inability of the kidney to produce erythropoietin.  Although the two 
types of anemia are often present concurrently and share some symptomatic indicators, they are 
considered to be distinct conditions with different eitologies235.  Therefore, inflammation further 
exacerbates the declining nutritional state of patients who already experience a derangement of 
nutrient metabolism due to renal insufficiency.     
Because protein malnutrition in dialysis patients promotes inflammation, it has been 
suggested that improving nutritional status may help halt this cycle of inflammation and 
decreased nutritional status60. If so, this could have a beneficial effect on many CKD co-
morbidities influenced by inflammation, particularly CVD56, 72.  In response to these issues, the 
National Kidney Foundation has recommended an increase in the protein requirement to 1.2 
g/kg/day for hemodialysis patients in comparison to the 0.8 g/kg/day recommended for healthy 
adults and 0.6 g/kg/day recommended for earlier stages of CKD. This recommendation was 
based on several small prospective nutritional-metabolic studies indicating this intake level is 
necessary to ensure neutral or positive nitrogen balance in most dialysis patients10.  However, 
most dialysis patients do not consume this recommended amount of protein, and a large multi-
center study of dialysis patients showed protein and calorie intake to be significantly lower on 
dialysis treatment days compared to non-treatment days219.  The combination of amino acids lost 
into the dialysate, suppressed nutrient intake on dialysis days, and the catabolic effects of dialysis 
treatment suggests that the time immediately prior to initiation of treatment would be most 
appropriate to administer a protein intervention to potentially offset the negative effects of 
dialysis.   
The purpose of this study was to determine the effects of whey and soy protein 
supplementation on acute inflammation over the course of a dialysis treatment.  While both 
protein sources will increase substrate availability, they differ in amino acid composition and 
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presence of other bioactive compounds such as soy isoflavones.  We hypothesized protein 
supplementation, both WHEY and SOY, would attenuate the increase in inflammation (IL-6) 
associated with the dialysis procedure.  Furthermore, we expected to see a greater attenuation in 
the SOY group due to bioactive components of soy protein.  
   
Subject Recruitment, Screening, and Selection.  Individuals with CKD receiving hemodialysis 
treatment at the Champaign-Urbana Dialysis Center in Champaign, IL (n=32) and the Oak Park 
Dialysis Clinic in Oak Park, IL (n=12) were recruited at their respective clinics.  Patients that 
met the following criteria were enrolled in the study:  1) Subjects must receive hemodialysis 
treatment at least 3 days per week. 2) Subjects must be ≥ 30 years of age. 3) Subjects must not 
have congestive heart failure or chronic obstructive pulmonary disease 4) Subjects must have 
been receiving dialysis treatment for ≥ 3 months as disruption in metabolic factors is related to 
duration of dialysis treatment.  A Health and Medical History Questionnaire was administered 
during the screening, and informed consent was obtained from each participant.  After consent 
was obtained, participants were randomly assigned to one of three groups: whey protein 
(WHEY), soy protein (SOY), or placebo/control (CON).  All research protocols were conducted 
with the approval of the University of Illinois Institutional Review Board.  Information on 
participant recruitment, enrollment, and study completion is provided in Figure 6.1.   
Methods 
 
Blood Collection.  The study protocol consisted of two blood draws per day on two separate 
days, one week apart (Figure 6.2).  The first draw was taken immediately after the initiation of 
dialysis and then again 3 hours into dialysis treatment.  On Day 1, participants did not receive a 
study beverage (control day) but had the two blood draws as described above.  The first draw on 
Day 1 is referred to as “baseline”.  On Day 2, one week following Day 1, each participant 
received the study beverage to which they had been randomly assigned and consumed the 
beverage immediately prior to the initiation of dialysis treatment.  After they consumed the 
beverage, blood was collected at the two time points described above.  Therefore, each patient 
had one control day and one treatment day to allow for comparison of the treatment effect to 
their normal inflammatory response to dialysis treatment. Plasma was collected by centrifugation 
and divided into 1ml aliquots and stored at -80oC until analyzed.   
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Blood collections were not performed on Mondays or Tuesdays to control for the extra 
day between treatments that occurs during the weekend.  For example, blood would not be drawn 
for a Monday/Wednesday/Friday scheduled patient on a Monday as they would not have 
dialyzed since Friday (two day lapse).  For a Tuesday/Thursday/Saturday scheduled patient, 
blood would not be drawn during their treatment on Tuesday for the same reason.  All blood 
chemistries and data analysis were performed in Champaign, IL regardless of collection site. 
    
Intervention: Protein Supplementation. Participants were given 30 grams of either a whey 
protein beverage, soy protein beverage, or placebo beverage immediately before dialysis 
treatment as described above.  Components of the protein beverages are listed in Table 6.1.  The 
whey beverage (True Protein, Inc., Oceanside, CA) contained 27 grams of cold-filtered whey 
protein isolate per 30 gram serving, with 110 calories per serving.  The soy protein supplement 
(Solae, Gibson City, IL) contained 27 grams of soy protein isolate (Supro 670) per 32 gram 
serving, with 120 calories and 1.5 grams of fat.  This soy protein isolate provided 40 milligrams 
of isoflavones per serving (12 mg daidzein, 22 mg genistein, 6 mg glycitein).  Supplements were 
matched for protein amount, resulting in a slightly higher total gram amount of the soy protein 
supplement.  The powders were mixed with a flavor pack containing natural/artificial flavors and 
colors, sucralose, and acesulfame k, and were prepared with 4-6 ounces of water for 
consumption.  Both protein powders provided sodium, iron, phosphorus, calcium, and other 
nutrients that are of concern for dialysis patients; however, the levels provided in this beverage 
were lower than those in a commercially available renal-specific formulation at the same level of 
protein (Nepro, Abbott Nutrition, Columbus, OH).  Patients in the CON group received 4-6 
ounces of non-caloric Crystal Light prepared according to package directions (Kraft, Northfield, 
IL).  
 
Blood Chemistry.  Circulating levels of the inflammatory marker interleukin-6 were measured 
at all four study time points using commercially available ELISA kits (R&D Biosystems, 
Minneapolis, MN).  In addition, blood collected at the dialysis clinic during normally scheduled 
blood draws was assessed for standard clinical lab parameters (plasma albumin, phosphorus, 
calcium, etc.) by a Spectra Laboratories, a renal specific laboratory service provider (Rockleigh, 
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NJ).  Reported transferrin saturation is the ratio of serum iron and total iron-binding capacity, 
multiplied by 100.     
 
Anthropometric Measures. Barefoot standing height was measured to the nearest 0.1 cm with a 
stadiometer and body weight was measured on a balance scale with shoes and superfluous outer 
garments removed. All measurements were taken in duplicate and averaged. 
 
Statistical Analysis. Data presented are mean ± SEM unless otherwise noted, and significance 
was considered as p<0.05.  Change in IL-6 levels was calculated using the following method: 
Δ Day 1 = Time Point 2 on Day 1 (3 hours into dialysis) minus Time Point 1 on Day 1 (start of 
dialysis); Δ Day 1 represents the change in IL-6 during dialysis with no study beverage.  Δ Day 2 
= Time Point 2 on Day 2 (3 hours into dialysis) minus Time Point 1 on Day 2 (start of 
dialysis/consumed study beverage); Δ Day 2 represents the change in IL-6 during dialysis with 
the study beverage.   
  Using the Δ values calculated above, Δ Day 2 minus Δ Day 1 represents the difference of 
the change in IL-6 during dialysis after consuming the study beverage compared to the 
difference in change of IL-6 during dialysis with no study beverage
Distribution statistics were calculated to determine whether assumptions of normality 
were met (including skewness and kurtosis between -2 and 2).  For some analyses, data from 
WHEY and SOY were combined to look at the effects of protein supplementation, regardless of 
source; this combined group assessing general protein intake is labeled PRO.  Correlation 
analysis was used to identify relationships between selected variables of interest.  Multiple linear 
regression analysis was used to determine predictors of intradialytic change in plasma IL-6 
levels.  For linear regression analysis gender and diabetes status were coded as follows:  male=1, 
female=2; diabetes=1, no diabetes=2.  All analyses were conducted using SPSS v.17 (Chicago, 
IL).     
.  The “Δ Day 2 minus Δ Day 
1” variable was analyzed using ANOVA to compare means among the three treatment groups.  
Time point 1 and 3 on each day and Δ values for Day 1 and Day 2 were analyzed by paired 
samples t-test.     
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Patient Characteristics.  A total of 44 hemodialysis patients (WHEY, n=20; SOY, n=15; CON, 
n=9) completed this study.  Patient characteristics are listed in Table 6.2.  There were no 
significant group differences for age, weight, BMI, albumin levels, transferrin saturation, 
hemoglobin, hematocrit, or iron.  According to the National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative (KDOQI™), patients were in normal range for transferrin saturation 
(20-50%), albumin (3.5-5.5 g/dL), and iron (30-160 mcg/dL) and were slightly low compared to 
the reference range for hematocrit at 37-47%  and hemoglobin at 12-16 g/dL.         
Results 
 
Intradialytic Change in Plasma IL-6 Concentration (Three Group Analysis). Intradialytic 
changes in plasma IL-6 concentration are shown for WHEY (n=20), SOY (n=15), and CON 
(n=9) in Figure 6.3.  All IL-6 values are expressed in ng/mL.  On Day 1, plasma IL-6 increased 
by 2.94±1.2, 6.92±1.4, 3.00±1.2 in WHEY, SOY, and CON, respectively.  The increase within 
each group was significant (p<0.01), but there were no between-group differences Δ Day 1.  On 
Day 2, IL-6 increased 2.68±0.86, 3.45±1.4, 5.24±2.1 for WHEY, SOY and CON; the increase 
within each group was significant (p<0.05).  The “Δ Day 2 minus Δ Day 1” mean values were -
1.28±1.2, -3.47±1.6, and 2.24±1.6 for WHEY, SOY, and CON with a trend toward a significant 
time by treatment interaction (p=0.065).  Comparison of within group differences between Δ 
Day 1 and Δ Day 2 showed SOY was significantly lower from Day 2 to Day 1 (p<0.05) while 
the differences within WHEY and CON between Δ Day 2 and Δ Day 1 were not significant.    
 
Intradialytic Changes in Plasma IL-6 Concentration (Two Group Analysis). Intradialytic 
changes in plasma IL-6 concentrations are shown for PRO (n=35) and CON (n=9) in Figure 6.3.  
On Day 1, IL-6 increased by 5.23±0.94 in PRO and increased 3.01±1.22 in CON; the increase 
within each group was significant, but there were no between-group differences for   change in 
IL-6 under the condition of no beverage on Day 1.  On Day 2, PRO increased by 3.01±0.79 
while CON increased by 5.24±2.1; again, the increase within each group was significant and 
there were no between group differences.   
There was a significant time by treatment interaction for “Δ Day 2 minus Δ Day 1”;  
mean values were significantly lower in PRO (-2.22±0.98) compared to CON (2.23±1.6) 
(p<0.05), suggesting protein supplementation attenuates the intradialytic increase in plasma IL-6 
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by around 2 pg/mL.  Although the “Δ Day 2 minus Δ Day 1” variable for the CON was positive 
(2.23±1.6), paired sample t-test analysis confirmed the within-group difference between Δ Day 1 
and Δ Day 2 was not significantly different for CON between no beverage day and beverage day 
(p=0.196); paired sample t-test analysis of PRO for Δ Day 2-Δ Day 1 was significant (p<0.05), 
suggesting an effect of treatment on Day 2.  Furthermore, ANOVA of the mean “Δ Day 2 minus 
Δ Day 1” as described above confirmed the significant time by treatment effect when mean 
differences in change were compared between CON and PRO.     
 
Relationship of IL-6 to Albumin, Serum Iron, and Transferrin Saturation. We found a 
significant inverse relationship between plasma albumin levels and both baseline IL-6 
concentration (r=-0.451, p<0.01) (Figure 6.4) and change in IL-6 on Day 1 (=-0.484, p<0.01) 
(Figure 6.5).  There was a significant negative association between plasma transferrin saturation 
and both baseline IL-6 concentration (r=-0.348, p<0.05) (Figure 6.6) and change in IL-6 on Day 
1 (r=-0.378, p<0.05) (Figure 6.7); serum iron was also inversely related to baseline IL-6 (r=-
.356, p<0.05) and change in IL-6 on Day 1 (r=-0.407, p<0.01).  However, only baseline IL-6 was 
predictive of change in IL-6 in a model that included gender, time on dialysis, diabetes status, 
albumin, and transferrin saturation (Table 6.3).    
 
We found that oral administration of 27 grams of protein immediately before dialysis 
treatment attenuates the increase in IL-6 associated with treatment, the first study to suggest the 
potential anti-inflammatory effects of intradialytic protein supplementation.  In addition, baseline 
IL-6 and the intradialytic change in IL-6 were inversely related to circulating albumin, transferrin 
saturation, and iron.   
Discussion 
CKD is a chronic inflammatory condition, as reflected in dialysis patients by elevated 
circulating levels of acute phase proteins such as CRP, and pro-inflammatory cytokines such as 
IL-6, and TNF-a56-59.  The dialysis procedure also induces an acute inflammatory response230, 233;  
we were able to confirm the increase in IL-6 that occurs during dialysis treatment by showing an 
increase in IL-6 on Day 1 when no treatment was administered, although the increase may be 
due in part to hemoconcentration occurring during treatment.  However, by measuring each 
person under the same dialysis conditions on both days, this effect was minimized and allowed 
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for a relative comparison of the effect of protein supplementation on inflammation during 
dialysis. 
In a study by Caglar and colleagues, IL-6 levels in hemodialysis patients peaked during a 
2-hour post dialysis phase233, but we chose to collect blood at 3 hours into dialysis treatment in 
order to minimize the burden of the patient to remain in the clinic for several hours after 
completing dialysis treatment.  While it is unclear what the effects of protein supplementation 
would be in this post-dialysis phase, we were able to demonstrate an effect of protein at the three 
hour time point.  Furthermore, our study had a larger number of subjects (n=44) compared to the 
Caglar study (n=9) that may have allowed for earlier detection of the increase in IL-6 that occurs 
in conjunction with dialysis treatment. 
We were able to show that intradialytic protein supplementation attenuates the increase in 
inflammation associated with the dialysis procedure.  We compared the change in IL-6 over a 
dialysis session in patients on both a control day and a treatment day, allowing for better control 
over the variability of the inflammatory response in these patients.  Although we were able to 
find an acute benefit, the beneficial long term effects of this acute reduction are unknown.  
Bossola et al reported time on dialysis was associated with improvements in nutritional status 
and a trend towards a reduction in inflammatory variables over a three year period107, which 
seems contrary to current evidence considering the acute pro-inflammatory and catabolic effects 
associated with dialysis treatment compounded over time.  The authors concluded time on 
dialysis was not necessarily associated with a decline in nutritional status or increase in 
inflammation; however, patients routinely received an intradialytic meal containing 25-30 grams 
of protein.  Because this meal was given as part of routine care, they did not consider it to be part 
of the study protocol.  This suggests routine intradialytic protein and/or calorie intake may be 
responsible for attenuating the decline in nutritional status and increased inflammatory state 
associated with long-term dialysis treatment.  However, this study lacked a control group and 
failed to provide information on subject compliance for this intradialytic meal, and more well-
controlled studies are clearly needed to see if the acute reduction shown in our current study 
would translate into long term beneficial outcomes. Furthermore, the effects of protein 
supplementation on functional outcomes related to inflammation in CKD patients, including 
cardiovascular risk and bone disease, warrant further investigation.        
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Although we demonstrated the attenuation of the increase in IL-6 in the protein combined 
protein group, we saw a trend for a time by treatment interaction when all three groups were 
considered (p=0.065).  Although the overall time by treatment interaction was not significant, the 
within-group difference for SOY was significantly lower for Δ Day 2 compared to Δ Day 1 
(p<0.05).   Therefore, it may be possible that the source of the protein may be a factor in 
determining the intradialytic inflammatory response to protein supplementation.  Fanti and 
colleagues demonstrated a marked inverse relationship between plasma CRP levels and the 
change in plasma isoflavone concentration measured before and after an 8-week supplementation 
with 25 grams of intradialytic soy protein118; they also noted a significant positive correlation 
between change in plasma isoflavone concentration and plasma albumin levels measured at the 
end of the study.  A milk protein supplement was used as the control in this study, and the 
authors did not report on the relationship between milk protein intake and plasma albumin levels 
albumin, making it difficult to determine if the association of isoflavones and albumin was due to 
the protein component of the supplement or a function of the bioactive isoflavones found in soy.  
However, this study and others suggest a possible relationship between soy protein consumption 
and inflammation during dialysis treatment.   
Protein supplementation during dialysis treatment, regardless of the protein source, will 
increase substrate availability, and this may help explain the modest effect of whey protein when 
the three groups were analyzed separately.  Compared to soy protein, whey protein contains 
higher amounts of the branch-chain amino acids leucine, isoleucine, and valine.  Leucine 
concentrations are especially important during a highly catabolic condition, and high amounts of 
leucine have been shown to potently stimulate muscle protein synthesis and inhibit protein 
breakdown in skeletal muscle and liver (reviewed in128).  Therefore, intradialytic whey protein 
supplementation may potentially mediate the inflammatory state by reducing catabolism through 
increased availability of amino acids.  Intradialytic protein supplementation may be particularly 
efficacious because it improves protein balance during the time when protein catabolism is at its 
peak10, 98, 99. Studies have shown that both parenteral100-102 and oral96, 103, 104 intradialytic 
supplementation improve protein homeostasis, increase serum albumin and prealbumin levels, 
and have anabolic effects on skeletal muscle, but the relationship of intradialytic protein 
supplementation and inflammation has not been previously demonstrated.  While we did not 
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measure protein catabolism in this study, we hypothesize that substrate availability from protein 
administration may directly or indirectly decrease catabolism by reducing inflammation. 
 Although serum albumin levels have traditionally been used as a marker of nutritional 
status, evidence suggests that inflammatory cytokines partly determine the levels of albumin in 
dialysis patients66, 236, making it difficult to separate the effects of inflammation and malnutrition 
on this negative acute phase protein.  Indeed, we found albumin levels to be related to not only 
baseline IL-6 levels, but also the magnitude of increase in IL-6 during dialysis treatment.  This 
suggests that presence of malnutrition, or increased inflammation, as indicated by albumin 
levels, is associated with the amount of increase in inflammation during dialysis treatment with 
more inflamed patients having a greater intradialytic inflammatory response.   
We found the same negative relationship with both serum iron and transferrin saturation 
(ratio of serum iron to total iron binding capacity) with baseline IL-6 and change in IL-6.  
Because serum iron is used to calculate transferrin saturation, the data for serum iron are not 
shown.  These markers are strongly influenced by inflammation, and the relationship with 
inflammation has caused their usefulness as markers of iron status to be questioned.  Beerenhout 
and colleagues showed a positive association between serum ferritin and C-reactive protein 
levels and an inverse relationship of transferrin saturation in hemodialysis patients237, while 
Nanami et al suggested inflammatory cytokines may be causing iron to be sequestered 
intracellularly due to changes in iron transporters in the cells induced by TNF-a238.  Intracellular 
sequestering of iron decreases available serum iron and transferrin saturation and also induces 
increased production of ferritin, the primary intracellular iron storage protein.  Both anemia of 
chronic disease, often termed anemia of inflammation, and iron deficiency anemia are 
characterized by low serum iron and low transferrin;  however, while levels of ferritin >30ng/mL 
are highly predictive of iron deficiency anemia, anemia of inflammation has marked increases in 
ferritin in response to the large amount of iron being sequestered intraceullarly in a state of 
inflammation (reviewed in 235).  While we did not see any relationship between ferritin levels and 
IL-6 in this study, the mean value for ferritin was 949±91 ng/mL, suggesting the influence of 
inflammation.  These data indicate serum iron, transferrin saturation, and ferritin are strongly 
related to the inflammatory state in hemodialysis patients and should be considered in that 
context.       
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There were several limitations to this study.  Participants were enrolled in this acute study 
as part of a larger, longer intervention trial in which they were randomly assigned to four groups, 
two of which receive whey protein supplementation (one alone, one in combination with exercise 
training).  This resulted in a larger number of participants randomly assigned to receive whey 
protein.  Additionally, we need to confirm the possible anti-inflammatory effect of intradialytic 
protein with other measures of inflammation that were not included in this study, and the 
relationships between acute intradialytic protein supplementation and the inflammatory response 
and other factors such as oxidative stress need to be examined in a more comprehensive manner. 
To our knowledge, this is the first study to suggest the benefits of intradialytic protein 
administration for attenuating the acute inflammatory response associated with the dialysis 
treatment procedure.  Because patients typically dialyze three to four times per week for up to 5 
hours per session, we believe the potential to mitigate the inflammatory and catabolic insult of 
repeated dialysis treatment has the potential to improve health outcomes over time.  In particular, 
studies are needed to assess the effects of chronic intradialytic protein supplementation on CKD 
co-morbidities associated with inflammation including CVD, bone disorders, muscle wasting, 
anorexia, and overall quality of life.  Intradialytic protein supplementation represents a low-cost, 
easy to administer therapeutic intervention that has the potential to improve health outcomes in 
hemodialysis patients.        
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Tables 
Table 6.1:  Composition of Whey Protein Isolate, Soy Protein Isolate, and Placebo Beveragea  
 
Per Serving Whey Isolate (30g) 
True Protein, 
Oceanside, CA 
Soy Isolate (32g) 
Solae, Gibson City, IL 
 
Crystal Light (2g) 
Kraft, Northfield, IL 
Total Fat    0 g   0.9 g 0 g 
Saturated Fat   0 g  0.3 g 0 g 
Cholesterol  0 mg  0 mg 0 mg 
Sodium  53 mg  373 mg 35 mg 
Carbohydrates  0 g  0 g 0 mg 
Protein  27 g  27 g 0 mg 
     Leucine 3.3g 2.1g 0 mg 
Vitamin A  0 mg  <2% 0 mg 
Vitamin C  0 mg  <2% 0 mg 
Calcium  151 mg  23 mg 0 mg 
Iron  0 mg  4.5 mg 0 mg 
Phosphorus 72.6 mg 244 mg 0 mg 
Potassium 194 mg 182 mg 0 mg 
Isoflavones 0 mg 40 mg 0 mg 
aComposition analysis was performed by a third-party laboratory at the University of Missouri 
 
 
Table 6.2:  Patient Characteristics and Selected Plasma and Serum Variables 
 
Participant Demographics  WHEY (n=20) SOY (n=15) CON (n=9) p-value 
   Gender 75.0% 53.3% 55.6%  
   Age (years) 54.5±4.1 54.9±2.8 52.8±3.8 0.920 
   Weight (kg) 91.5±5.5 96.6±6.1 96.5±10.7 0.813 
   BMI (kg/m2) 31.4±1.8 35.3±2.5 34.3±3.1 0.406 
   Smoking Status (yes) 22.2% 40% 26.7%  
   Type II Diabetes (yes) 40% 33.3% 66.7%  
Plasma/Serum Variables     
   Transferrin Saturation (%) 43.9±3.7 33.5±2.5 33.8±6.4 0.198 
   Albumin (g/dL) 3.98±0.07 3.97±0.10 4.00±0.11 0.983 
   Iron (mcg/dL) 99.2±9.2 77.8±6.2 81.4±16.4 0.263 
   Hemoglobin (g/dL) 15.5±3.9 11.7±0.32 11.6±0.44 0.611 
   Hematocrit (%) 35.7±0.88 36.0±0.91 35.6±1.4 0.968 
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Table 6.3:  Factors related to intradialytic change in plasma IL-6 
 Δ Day 1 R2=0.356, p<0.002 
Variable T p B 
Gender 0.707 0.486 1.05 
Diabetes -1.41 0.170 -2.21 
Time on 
Dialysis 
0.848 0.403 0.015 
Baseline IL-6 2.90 0.007 0.273 
Albumin -1.04 0.307 -2.82 
Trans Sat -0.752 0.458 -0.114 
Iron 0.535 0.596 0.034 
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Figures  
Figure 6.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1:  Recruitment, Enrollment, and Study Completion. 
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Figure 6.2 
 
 
 
Figure 6.2:  Study timeline.  On Day 1, the first draw was taken immediately after the initiation 
of dialysis and then again 3 hours into dialysis treatment.  On Day 2, one week following Day 1, 
each participant received the study beverage to which they had been randomly assigned and 
consumed the beverage immediately prior to the initiation of dialysis treatment after which blood 
was collected at the two time points described above.   
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Figure 6.3   
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Figure 6.3:  Comparison of change in IL-6 from Day 1 to Day 2 (Three Group and Two Group 
Analysis).  A “*” indicates significantly lower increases in IL-6 on Day 2 compared to Day 1 for 
SOY (p<0.05) and combined PRO (p<0.05) analyzed by paired sample t-test for within-group 
changes.  There was significant time by treatment effect for the Two Group analysis (§ indicates 
p<0.05 for interaction).  Changes are presented as mean ± SEM. 
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Figure 6.4 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 6.4: Correlation of plasma IL-6 at baseline with plasma albumin.  Baseline IL-6 was 
inversely related to plasma albumin (r=-0.415, p<0.01).  
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Figure 6.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5:  Correlation of change in plasma IL-6 on Day 1 with plasma albumin.  The change in 
IL-6 from Time Point 1 to Time Point 3 on Day 1 was inversely related to plasma albumin (r=-
0.484, p<0.01). 
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Figure 6.6 
 
Figure 6.6:  Correlation of plasma IL-6 at baseline with transferrin saturation.  Baseline  
IL-6 was inversely related to transferrin saturation (r=-0.348, p<0.05). 
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Figure 6.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7:  Correlation of change in plasma IL-6 on Day 1 with transferrin saturation.  The 
change in IL-6 from Time Point 1 to Time Point 3 on Day 1 was inversely related to transferrin 
saturation (r=-0.378, p<0.05). 
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CHAPTER 7 
 
LONG-TERM EFFECTS OF INTRADIALYTIC PROTEIN SUPPLEMENTATION 
 
Protein-energy malnutrition is very common in dialysis patients, with the incidence rate 
ranging from 25% to 75% in different studies6-9. There are a variety of reasons for this, including 
poor nutrient intake, physical illnesses affecting gastrointestinal function, protein losses during 
dialysis, and elevated whole body and skeletal muscle protein catabolism that occurs primarily 
during dialysis (reviewed in10). Protein malnutrition is associated with a loss of lean mass and 
declines in physical function in hemodialysis patients. These functional declines reduce physical 
activity levels, which exacerbates the development of co-morbidities like cardiovascular disease 
(CVD) and bone disorders. This cycle of disease and disability greatly reduces the quality of life 
(QOL) and increases mortality in dialysis patients11, 12. 
Introduction 
In response to these issues, the National Kidney Foundation has recommended an 
increase in the protein requirement to 1.2 g/kg/day for hemodialysis patients in comparison to the 
0.8 g/kg/day recommended for healthy adults and 0.6 g/kg/day recommended for earlier stages 
of Chronic Kidney Disease (CKD). This recommendation was based on several small 
prospective nutritional-metabolic studies indicating this intake level is necessary to ensure 
neutral or positive nitrogen balance in most dialysis patients10.  However, most dialysis patients 
do not consume this recommended amount of protein, and a large multi-center study of dialysis 
patients showed protein and calorie intake to be significantly lower on dialysis treatment days 
compared to non-treatment days219.   
The combination of amino acids lost into the dialysate, suppressed nutrient intake on 
dialysis days, and the catabolic effects of dialysis treatment suggests that the time immediately 
prior to initiation of treatment would be most appropriate to administer a protein intervention to 
potentially offset the negative effects of dialysis.  Furthermore, intradialytic supplementation 
may be particularly efficacious in improving protein balance since it is provided during the time 
when protein catabolism is at its peak10, 98, 99.  Leucine concentrations are especially important 
during a highly catabolic condition as high amounts of leucine have been shown to potently 
stimulate muscle protein synthesis and inhibit protein breakdown in skeletal muscle and liver128.  
Studies have shown that both parenteral100-102 and oral96, 103, 104 intradialytic supplementation 
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improve protein homeostasis, increase serum albumin and prealbumin levels, and have anabolic 
effects on skeletal muscle. However, oral supplementation is much more practical than parenteral 
due to high costs and restrictions on the use of parenteral nutrition by Medicare and other 
insurance providers.  Furthermore, it is not known if these acute anabolic effects translate to 
long-term benefits on functional outcomes in this population.   
The purpose of this study was to test the efficacy of six months of intradialytic protein 
supplementation, with either whey or soy protein, on CKD co-morbidities including measures of 
cardiovascular disease risk, bone health, measures of physical performance, body composition, 
QOL, and clinically relevant plasma markers.  We hypothesized that protein supplementation, 
regardless of source, would improve functional outcomes by increasing substrate availability to 
attenuate protein catabolism and associated inflammation.  For functional measures, we expected 
to see the greatest effect in whey protein supplementation compared to soy owing to the larger 
ratio of leucine, while we expect greater effects on bone parameters from soy protein due to the 
bioactive isoflavones.   
 
Subject Recruitment, Screening, and Selection.  Individuals with CKD receiving hemodialysis 
treatment at the Champaign-Urbana Dialysis Center in Champaign, IL and the Oak Park Dialysis 
Clinic in Oak Park, IL were recruited at their respective clinics.  Patients that met the following 
criteria were enrolled in the study:  1) Subjects must receive hemodialysis treatment at least 3 
days per week. 2) Subjects must be ≥ 30 years of age. 3) Subjects must not have congestive heart 
failure or chronic obstructive pulmonary disease 4) Subjects must have been receiving dialysis 
treatment for ≥ 3 months as disruption in metabolic factors is related to duration of dialysis 
treatment.  5) Subjects must weight <300 pounds due to weight limitations on the dual x-ray 
absorptiometry (DXA) table.  A Health and Medical History Questionnaire was administered 
during the screening, and informed consent was obtained from each participant. 
Methods 
After consent was obtained, participants were randomly assigned to one of three groups: 
whey protein (WHEY, n=5), soy protein (SOY, n=6), or placebo/control (CON, n=7).  All 
research protocols were conducted with the approval of the University of Illinois Institutional 
Review Board.  Recruitment and retention information is provided in Figure 7.1. 
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Intervention Protocol: Protein Supplementation. Participants were given either a whey 
protein beverage, soy protein beverage, or placebo beverage immediately before every dialysis 
treatment for six months.  Components of the protein beverages are listed in Table 7.1.  The 
whey protein powder (True Protein, Inc., Oceanside, CA) contains 27 grams of cold-filtered 
whey protein isolate per 30 gram serving, with 110 calories per serving.  The soy protein powder 
(Solae, Gibson City, IL) contains 27 grams of soy protein isolate (Supro 670) per 32 gram 
serving, with 120 calories and 1.5 grams of fat.  This soy protein isolate provides 40 milligrams 
of isoflavones per serving (12 mg daidzein, 22 mg genistein, 6 mg glycitein).  Supplements were 
matched for protein amount, resulting in a slightly higher total gram amount of the soy protein 
supplement.  The powders were mixed with a flavor pack containing natural/artificial flavors and 
colors, sucralose, and acesulfame k, and were prepared with 4-6 ounces of water for 
consumption.  Both protein powders provided sodium, iron, phosphorus, calcium, and other 
nutrients that are of concern for dialysis patients; however, the levels provided in this beverage 
were lower than those in a commercially available renal-specific formulation at the same level of 
protein (Nepro, Abbott Nutrition, Columbus, OH).  Patients in the CON group received 4-6 
ounces of non-caloric Crystal Light prepared according to package directions (Kraft, Northfield, 
IL).  Compliance was tracked for each patient and a level of 75% compliance was established for 
remaining in the study. 
 
Clinical Testing and Measurements. At baseline and immediately following the 6 month 
intervention (final testing), all patients underwent a series of tests described below to evaluate 
the effects of the intradialytic protein supplementation on our primary outcomes. All testing 
sessions, with the exception of blood collections were conducted on a non-dialysis day 18-24 
hours following a dialysis treatment. All testing was analyzed by study personnel blinded to the 
subject’s group assignment.  Blood collections were not performed on Mondays or Tuesdays to 
control for the extra day between treatments that occurs during the weekend.  For example, blood 
would not be drawn for a Monday/Wednesday/Friday scheduled patient on Monday as they 
would not have dialyzed since Friday (two day lapse).  For a Tuesday/Thursday/Saturday 
scheduled patient, blood would not be drawn during their treatment on Tuesday for the same 
reason.  All testing was done on identical equipment at both sites; all blood chemistries and data 
analysis were performed in Champaign, IL regardless of collection site. 
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Anthropometric Measures. Barefoot standing height was measured to the nearest 0.1 cm with a 
stadiometer and body weight was measured on a balance scale with shoes and superfluous outer 
garments removed. All measurements were taken in duplicate and averaged. 
 
Blood Chemistry.  Prior to the start of the intervention, and at monthly intervals until the final 
testing session (7 total time points), non-fasted blood was collected at the dialysis clinic during 
normally scheduled blood draws and assessed for standard clinical lab parameters (plasma 
albumin, phosphorus, calcium, etc) by Spectra Laboratories, a renal specific laboratory service 
provider (Rockleigh, NJ)..    
 
Carotid Arterial Compliance. A combination of ultrasound imaging of the common carotid 
artery with simultaneous arterial tonometry of the contralateral carotid artery (for estimation of 
carotid blood pressure was used to determine carotid arterial compliance. Carotid ultrasound 
images were obtained from the common carotid artery, 1-2 cm proximal to the carotid 
bifurcation using a 7-13 MHz linear array transducer with a sampling rate of 1000 Hz. B-Mode 
and M-mode images were obtained and displayed simultaneously and automated wall tracking 
software was used to detect changes in lumen size as described above. The electronic calipers 
were applied to the arterial wall using the B-mode image and wall tracking was conducted using 
the M-mode image in real time. Changes in lumen size between systole and diastole were 
recorded for 12 seconds and an ensemble average beat were constructed from which 
measurements of arterial compliance and stiffness were calculated. Arterial compliance (AC) and 
the beta stiffness index (β) were calculated together with lumen size in systole and diastole using 
the calculations shown below:  
 
-AC (arterial compliance: index of blood vessel compliance)= π(Ds ×Ds - Dd×Dd) / [4 (Ps – Pd)]  
-β (stiffness parameter: index of arterial stiffness) = In (Ps / Pd) / [(Ds – Dd) / Dd]  
 
Brachial blood pressure was obtained using standard methods following a 10 minute rest period. 
Pressures were corrected for hold down pressure. 
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 Bone Mineral Density and Body Composition. Bone mineral density (BMD) and whole-body 
soft tissue composition were measured by DXA using a Hologic QDR 4500A bone densitometer 
(software version 11.2, Bedford, Massachusetts) from scans of the whole body, lumbar spine and 
proximal femur.  All scans were analyzed and quality-controlled by the same two technicians 
blinded to treatment status.  Short and long-term accuracy of the densitometer was verified by 
scanning a manufacturer’s hydroxyapatite spine phantom of a known density. Precision for DXA 
measurements of interest are ~1.0 – 2.0% in our laboratory.  Mineral free lean mass (MFLM) 
was calculated from DXA values as lean mass of selected compartment – bone mineral content 
of selected compartment (whole body, trunk, leg, etc).   
 
Shuttle Walk Test.  Participants underwent a shuttle walk test to assess physical performance in 
which they walk back and forth continuously on a 10 meter course. The walking was paced by 
beeps which were programmed to have participants maintain each speed for one minute and then 
the pace was increased. The speeds increased so that in each successive minute the speeds were 
as follows: 1.12, 1.54, 1.88, 2.26, 2.64, 3.02, 3.4, 3.78, 4.16, 4.54, 4.92, and 5.3 miles per hour. 
The patient continued until they failed to achieve the distance to the end of the course by the 
beep and the total time was calculated. 
Measures of physical performance such as this shuttle walk test are frequently used to 
assess function in older and diseased people instead of more objective measures of aerobic 
capacity such as VO2max testing.  This is due to functional limitations like muscle weakness and 
shortness of breath that prevent these individuals from achieving standard criteria used in 
assessment of these more objective tests136.  This shuttle walk test is well established as a part of 
the guidelines for assessment of fitness in patients with chronic pulmonary disease213, and is 
often preferred to the six minute walk test because it is paced, and therefore more objective.  
 
Quality of Life Assessment.  Physical and mental health status was measured by the 12-Item 
Short Form Survey derived from the Medical Outcomes 36-item Short Form Survey214. Global 
QOL was measured by the Satisfaction with Life Scale215, 216. This measure is a cognitive 
judgment of one's life taken as a whole, and is usually thought to involve comparing one's life 
against some standard. These scales have been shown to be reliable and valid indices of 
components of subjective well-being.    
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Diet assessment.  Participants were given two 24- hour food recall interview with a trained 
researcher on consecutive days to account for variations in eating patterns associated with 
dialysis treatment.  The interview was conducted using a modified version of the United States 
Department of Agriculture 5-pass method: the first pass asked for the patients to recall 
everything they ate during the previous 24-hours, the second pass probed for foods that may have 
been forgotten including beverages, snacks, and condiments, the third pass included prompts for 
portion sizes and food amounts, the fourth pass asked for details about the food including brand 
names, and the fifth pass consisted of a final review of the record.  The records were analyzed for 
macronutrient composition and other dietary variables using Nutritionist Pro Data Analysis 
Software (Stafford, TX).  
 
Statistical Analysis. All data are presented as mean ± SEM, unless otherwise indicated.  
Significance was considered when p<0.05.  Generalized estimating equation (GEE) for 
longitudinal data was used to determine the effects of protein supplementation on monthly 
plasma variables.  Plasma variables were collected each month from baseline to final testing for a 
total of 7 time points/person.  The full model considers the interaction between time and 
treatment, controlling for gender, age, diabetes status, and smoking.  The full model is as 
follows, where “Y” represents each plasma variable of interest, and “Y0” represents that 
particular variable at baseline to control for any baseline variations: 
 
Y= β0 +  β1Y0 + β2treatment + β3gender + β4age + β5diabetes + β6smoking + β7time + 
β8time*treatment 
 
For some analyses, data from WHEY and SOY were combined to look at the effects of protein 
supplementation, regardless of source; this combined group assessing general protein intake is 
labeled PRO. Repeated measures analysis of variance (ANOVA) was used to determine time by 
treatment interaction for functional outcomes.  In the absence of significant interaction effect, 
Cohen’s d was calculated for effect size.  Correlation analysis was used to identify relationship 
between selected variables of interest.  Differences in nutrient intake between baseline and final 
testing were determined using paired-sample t-test for each treatment group.       
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Patient Characteristics. Subject characteristics at baseline are shown in Table 7.2, and the 
etiology of each patient’s renal failure is described in Table 7.3.  A total of 22 patients were 
recruited for this study, with 7 in WHEY, 8 in SOY, and 7 in CON.  One subject passed away 
during the study (unrelated to study protocol), 1 subject dropped out to due gastrointestinal 
distress, 1 participant withdrew for unknown reasons, and one participant withdrew after 
receiving a kidney transplant during the intervention period.  A total of 5 WHEY, 6 SOY, and 7 
CON participants completed the 6-month intervention protocol.  At baseline, the three groups did 
not differ significantly regarding age, body mass index (BMI), or any of clinical lab values.  
When protein groups were combined, there were also no significant differences between PRO 
and CON for any of the above factors.  All groups were within normal range for plasma albumin 
levels, but had elevated iPTH, phosphorus, and ferritin, and depressed total iron binding capacity 
(TIBC) (Table 7.2).  Levels of hematocrit and hemoglobin were marginally low in all groups 
compared to reference ranges suggested by the National Kidney Foundation Chronic Kidney 
Disease Outcomes Quality Initiative (NKF KDOQI). 
Results 
 
Plasma Variables. Results of analysis of monthly plasma variables representing seven time 
points per patient from baseline to final testing are shown in Table 7.4.  WHEY was associated 
with an increase of 0.051±0.07 mEq/L of bicarbonate/month (p<0.01), a decrease in phosphorus 
of 0.29±0.05 mg/dL per month (p<0.05), a decrease of ferritin/month of 25.6±8.1 ng/mL 
(p<0.05), a decrease of 0.15±0.02 mEg/L potassium/month (p<0.05), and an increase in 
TIBC/month of 1.1±0.7 mcg/dL (p<0.05).  When protein groups were combined, PRO was 
associated with a decrease in alkaline phosphatase of 5.4±3.5 U/L (p<0.05).  There were no 
significant time by treatment interactions for albumin, creatinine, hemoglobin, hematocrit, 
parathyroid hormone, blood urea nitrogen, calcium, iron, or transferrin saturation.   
 
Functional Outcome Measures and Baseline and Final Testing. We did not find any 
significant time by treatment effects for our outcomes of cardiovascular disease risk, QOL, bone 
health, or body composition.  Mean values at baseline and final testing are presented in Table 
7.5 along with calculated effect sizes (indicated by Cohen’s d).  We did not see any time by 
treatment effects for QOL (Total Disability Score, Satisfaction with Life Scale), bone measures 
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(Hip BMD, Whole Body BMD) or body composition (Whole Body MFLM , Whole Body % 
Fat).  For central pulse wave velocity (PWV), our primary cardiovascular outcome, there were 
no statistically significant interaction effects.  However, PRO had ~20% decrease in PWV 
(d=1.01) compared to an approximately 14% increase in PWV for CON (d=0.689). 
 
Physical Performance. There was a significant time by treatment interaction effect for Shuttle 
Walk test; average walk time for WHEY significantly improved from baseline to final (p<0.01), 
time significantly declined for CON (p<0.05) and SOY, although the decline for SOY was not 
significant (Figure 7.2).  When all groups were considered, change in Shuttle Walk time was 
positively correlated with TIBC measured at final testing (r=0.594, p<0.05) (Figure 7.3).  There 
was a trend for correlation of final TIBC and final Shuttle Walk Time in all treatment groups, 
although this was not significant (p=0.056).   
 
Diet Assessment. Protein intake per body weight was significantly higher on dialysis day at final 
testing compared to baseline (Figure 7.4); protein intake per body weight was not significantly 
different for non-dialysis day, but the average protein intake was significantly higher for PRO.  
There was no difference in protein intake for CON from baseline to final for dialysis or non-
dialysis days.  PRO had significantly higher intake of phosphorus and calcium on dialysis day at 
final compared to baseline (p<0.05).  There were no differences for any of the selected nutrients 
for CON from baseline to final testing (Table 7.6) including grams of protein, carbohydrates, fat, 
and overall caloric intake.    
 
The primary findings in this paper were that six months of intradialytic whey protein 
supplementation improved physical performance as assessed by Shuttle Walk Test time, and the 
change in time was associated with total iron binding capacity (TIBC); whey protein 
supplementation also was associated with increased plasma TIBC, increased bicarbonate, and 
decreased phosphorus, potassium, and ferritin.  When the protein groups were considered 
together, protein intake was associated with lower alkaline phosphatase (ALP).  Furthermore, 
intradialytic protein supplementation increased protein intake on dialysis day and average protein 
intake from baseline to final testing, adjusted for body weight.  Lastly, there was no significant 
Discussion 
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difference in pulse wave velocity in any group, but we saw a large effect size for reduction of 
pulse wave velocity in the PRO group (d=1.01) compared to an increase in PWV for CON 
(d=0.689).  Taken together, these data suggest the benefits of intradialytic protein 
supplementation, particularly for whey protein; perhaps in part due to the larger ratio of 
branched-chain amino acids present in whey protein.      
 We were able to demonstrate that the intradialytic supplementation we provided 
significantly increased protein intake on dialysis day in both groups receiving protein, while 
there was no change in protein intake in the control group.  Average intake reported in grams 
was not significantly increased in the PRO group from baseline to final as shown in Table 7.6, 
but when protein intake was normalized to body weight, the difference was statistically 
significant (Figure 4).   
This increase in protein intake on dialysis day was accompanied by a significant increase 
in phosphorus and calcium intake due in part to the protein supplement we provided.  
Hyperphosphatemia independently predicts morbidity and mortality in dialysis patients239 and 
both high phosphorus and calcium are associated with development of vascular calcification and 
other metabolic abnormalities240; for this reason patients are requested to restrict calcium and 
phosphorus,  often taking the form of protein restriction, which further exacerbates the 
malnutrition-inflammation complex commonly seen in this population.  However, despite the 
reported increase in dietary calcium and phosphorus, whey protein supplementation was 
associated with a significant decrease in plasma phosphorus of 0.288±0.06 mg/dL per month and 
no change was seen for either group in plasma calcium.  This suggests that intradialytic protein 
supplementation, although a source of dietary phosphorus and calcium, did not detrimentally 
affect circulating levels of phosphorus and calcium in this study.  Other studies have shown 
phosphorus intake does not , and other factors may be contributing more significantly to the 
regulation of these minerals in the blood.   
Patients receiving whey protein performed significantly better on the Walk Test from 
baseline to final compared to SOY and CON, who performed worse on average at final testing.  
We have previously observed in our lab that gender and diabetes status are significant predictors 
of walk test performance; however, the improvement for WHEY remained significant after 
controlling for these two factors.  Furthermore, performance on the Walk Test was associated 
with TIBC, suggesting a potential mechanism by which whey protein improves physical 
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performance.  In fact, we also showed whey protein to be associated with an increase in TIBC of 
over the intervention period.   
Low levels of TIBC and high ferritin levels, as seen in this study, suggest anemia of 
chronic disease, as the exact opposite would be observed in iron-deficiency anemia235.  Anemia 
of chronic disease, often termed anemia of inflammation, results in derangement of traditional 
markers of iron metabolism.  Ferritin, an acute phase protein, was well above desirable clinical 
ranges in all groups prior to this intervention, and intradialytic whey protein supplementation 
was associated with a 25.56±8.1 ng/mL decrease in ferritin levels per month of the study.  Many 
regard elevated ferritin levels to be a marker of inflammation in dialysis patients241, and this 
could potentially indicate an anti-inflammatory role for intradialytic protein supplementation.  
Because protein malnutrition in dialysis patients promotes inflammation, it has been suggested 
that improving nutritional status may help prevent inflammation60, and could explain the 
relationship between intradialytic whey supplementation and reduced levels of the acute phase 
protein ferritin.  Although the mechanism by which whey protein increases TIBC and decreases 
ferritin cannot be determined from the present study, improvement in iron metabolism and 
subsequent increase in red blood cell production could be partly responsible for the improvement 
in physical performance seen here.     
Levels of alkaline phosphate (ALP) have been shown to be inversely associated with 
bone mineral density in hemodialysis patients185, and positively associated with vascular 
calcification186 leading to increased cardiovascular risk in this population.  Furthermore, Regidor 
and colleagues reported elevated ALP to be an independent predictor of mortality in a 3-year 
cohort of over 70,000 dialysis patients, suggesting the clinical relevance of this marker226  We 
found PRO to be associated with a significant decrease of 5.39±3.5 U/L ALP per month during 
this study intervention.  We have previously demonstrated a reduction in ALP after 4-months of 
intradialytic exercise training242, but the mechanism for intradialytic exercise or protein-induced 
reduction in ALP is unknown at this time.   
There were several limitations to this study, most notably the small sample size.  The 
CON group had a large proportion of men (6:1), was generally younger, heavier, and had fewer 
smokers.  We have observed previously that gender is highly related to measures of fitness, 
strength, and cardiovascular disease risk in this population; also weight and gender predict bone 
mineral density and body composition, while smoking, age, and gender are all related to 
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cardiovascular disease outcomes in hemodialysis patients.  Therefore, the large proportion of 
relatively younger, non-smoking, heavier men in the placebo group may have masked some 
potential differences in study outcomes due to the very small sample size.  Larger, multi-center 
intervention trials are needed to expand on the findings of this current study.  Additionally, we 
did not control for patient medications with this study. 
 Despite the small sample size, we were able to demonstrate significant effects of protein 
supplementation on functional outcomes and relevant clinical markers in hemodialysis patients.  
In summary, we found intradialytic whey protein supplementation was associated with improved 
physical performance and improvements in plasma variables related to CKD co-morbidities.  We 
also found an association with lower ALP in patients receiving intradialytic protein, regardless of 
source.  Furthermore, we did not see any significant changes in plasma calcium or calcium 
phosphorus product despite significant increases for dietary intake of phosphorus and calcium in 
both protein groups on dialysis treatment day; conversely, we demonstrated whey protein was 
significantly associated with a decrease in plasma phosphorus over the 6- month intervention 
period.  In conclusion, intradialytic protein supplementation, particularly whey protein, induced 
modest favorable changes in functional outcomes and could represent a low-cost therapeutic 
treatment strategy for this critically ill population.      
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Tables 
Table 7.1:  Composition of Whey Protein Isolate, Soy Protein Isolate, and Placebo Beveragea  
Per Serving Whey Isolate (30g) 
True Protein, 
Oceanside, CA 
Soy Isolate (32g) 
Solae, Gibson City, IL 
Crystal Light (2g) 
Kraft, Northfield, IL 
Total Fat    0 g   0.9 g 0 g 
Saturated Fat   0 g  0.3 g 0 g 
Cholesterol  0 mg  0 mg 0 mg 
Sodium  48 mg  362 mg 35 mg 
Carbohydrates  0 g  0 g 0 mg 
Protein  27 g  27 g 0 mg 
     Leucine 2.9g 1.9g 0 mg 
Vitamin A  0 mg  <2% 0 mg 
Vitamin C  0 mg  <2% 0 mg 
Calcium  151 mg  23 mg 0 mg 
Iron  0 mg  4.5 mg 0 mg 
Phosphorus 64.5 mg 237 mg 0 mg 
Potassium 176 mg 176 mg 0 mg 
Isoflavones 0 mg 40 mg 0 mg 
aComposition analysis was performed by a third-party laboratory at the University of Missouri.   
 
Table 7.2:  Participant Characteristics at Baseline 
 
 WHEY 
(n=5) 
SOY 
(n=6) 
CON 
(n=7) 
p-value PRO 
(n=11) 
p-value 
Gender 60.0% 50.0% 85.7% 0.415 54.5%  
Age (years) 57.6±8.5 54.0±8.5 49.5±2.1 0.701 55.6±5.8 0.442 
Diabetic (yes) 40.0% 33.3% 57.1% 0.712 36.4%  
Smoker (yes) 60.0% 50.0% 28.6% 0.575 54.5%  
BMI (kg/m2) 28.9±3.1 29.2±2.4 35.6±3.8 0.276 29.1±1.8 0.103 
Albumin (g/dL) 4.04±0.11 3.93±0.06 3.99±0.08 0.698 3.98±0.06 0.969 
iPTH (pg/mL) 458±536 945±668 427±157 0.720 762±421 0.601 
Phosphorus 
(mg/dL) 
6.58±0.89 5.88±0.60 6.51±0.78 0.781 6.20±0.50 0.727 
Potassium (mEq/L) 4.80±0.28 4.70±0.43 4.84±0.31 0.956 4.74±0.25 0.813 
TransSat (%) 31.4±5.1 34.0±3.1 34.0±3.5 0.872 32.8±2.8 0.793 
TIBC (mcg/dL) 222±16 219±9 194±7 0.163 220±8 0.054 
Ferritin (ng/mL) 1007±81 852±193 739±190 0.397 922±59 0.264 
Iron (mcg/dL) 68.8±10.8 75.7±9.5 65.4±5.5 0.670 72.5±6.8 0.473 
Hematocrit (%) 36.5±1.6 37.2±0.89 36.5±1.2 0.891 36.9±0.84 0.778 
Hemoglobin (g/dL) 11.6±0.35 12.1±0.26 11.9±0.37 0.568 11.9±0.21 0.884 
Data are presented as mean ± SEM.  The first p-value column refers to differences among 
WHEY, SOY, and CON, and the second p-value refers to differences between PRO and CON. 
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Table 7.3:  Etiology of Renal Failure for Participants 
 
Etiology of Renal Failure WHEY SOY CON PRO 
Hypertension 80% (4) 50% (3) 57.1% (4) 63.6% (7) 
Diabetes w/ renal manifestations, Type 1  16.7% (1)  9.1% (1) 
Diabetes w/ renal manifestations, Type 2  16.7% (1) 28.6% (2) 9.1% (1) 
Polycystic Kidney Disease   14.3% (1)  
Nephritis/Nephropathy  16.7% (1)  9.1% (1) 
Unknown/Other 20% (1)   9.1% (1) 
Total 100% (5) 100% (6) 100% (7) 100% (11) 
 
 
 
Table 7.4:  GEE Modeling of Monthly Plasma Variables 
 
 WHEY p-
value  
SOY p-
value 
CON p-
value 
Bicarbonate (22-29mEq/L) 0.51±0.07 <0.01 -0.44±0.19 NS -0.14±0.19 NS 
Phosphorus (2.6-4.5 mg/dL) -0.29±0.06 <0.05 0.007±0.08 NS -0.02±0.05 NS 
Ferritin (22-322 ng/mL) -25.6±8.1 <0.01 15.4±4.5 NS 35.6±16.5 NS 
Potassium (3.5-5.1 mEq/L) -0.15±0.02 <0.05 0.02±0.01 NS 0.01±0.06 NS 
TIBC (228-428 mcg/dL) 1.07±0.65 <0.05 -1.30±0.74 NS -2.47±0.80 NS 
Data are presented as mean ± SEM.  P-values < 0.05 are considered significant.  GEE Modeling 
included 7 time points/per measure for each patient, and p-value represents significant time by 
treatment interaction in a model that included time, gender, diabetes status,  and smoking status.  
 
 
Table 7.5:  Functional Outcome Measures at Baseline and Final Testing 
 
 PRO (n=11) CON (n=7) 
 Baseline Final d Baseline Final d 
AI (%) 17.4±3.6 14.4±3.7 0.275 8.9±4.0 7.5±5.9 0.103 
β Stiffness (U) 9.60±0.80 11.10±1.6 0.3926 7.41±0.80 8.52±1.5 0.3440 
PWV (m/sec) 12.52±1.7 9.99±1.0 1.01 7.80±1.1 10.35±2.5 0.689 
Total Disability Score 57.8±3.0 59.5±3.5 0.163 61.4±4.0 59.9±4.8 0.129 
SWLS 20.1±2.2 20.8±2.7 0.087 18.0±3.5 19.1±3.1 0.131 
Hip BMD (g/cm2) 0.88±0.07 0.89±0.07 0.041 0.97±0.08 0.97±0.09 0.019 
Wb BMD (g/cm2) 1.06±0.05 1.07±0.04 0.063 1.13±0.07 1.14±0.07 0.031 
Wb MFLM (kg) 54.50±3.8 54.6±3.8 0.003 67.0±7.1 66.8±6.2 0.015 
Wb % Fat (%) 30.4±2.8 30.8±2.4 0.03 33.4±4.9 34.3±5.3 0.06 
Data are expressed as mean ± SEM.  Cohen’s d represents effect size.  AI=Augmentation Index, 
PWV=pulse wave velocity, SWLS=Satisfaction with Life Scale, BMD=Bone Mineral Density, 
Wb=Whole Body, MFLM=Mineral Free Lean Mass 
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Table 7.6:  Comparison of Selected Nutrients on Dialysis and Non-Dialysis Days as assessed by 
24-hour Dietary Recall , by Treatment Group  
 
 Dialysis Day Non-Dialysis Day Average 
 Baseline Final Baseline Final Baseline Final 
PRO:  Protein (g) 59.9±7.0 81.2±6.7* 76.4±12.8 79.7±15.2 68.2±7.4 80.4±9.7 
CON: Protein (g) 80.9±7.9 88.7±12.8 83.2±11.6 90.2±23.1 82.1±4.9 89.5±14.1 
       
PRO:  Carb (g) 153±15 163±34 173±21 178±30 163±14 170±23 
CON:  Carb (g) 188±38 157±35 177±30 190±43 183±31 173±32 
       
PRO:  Fat (g) 65.9±13.6 57.7±9.1 74.6±12.7 76.8±11.6 70.3±12.1 67.3±7.1 
CON: Fat (g) 61.9±9.8 66.0±12.8 61.6±6.2 60.0±17.3 61.8±4.3 63.0±11.4 
       
PRO:  Calories (kcal) 1421±180 1591±192 1648±206 1708±266 1535±174 1649±150 
CON:  Calories (kcal) 1626±248 1582±276 1542±155 1645±395 1584±170 1613±261 
       
PRO:  Phos (mg) 621±90 853±87* 910±195 1029±243 766±88 941±132 
CON:  Phos (mg) 704±122 1047±243 1016±271 1132±299 860±131 1090±220 
       
PRO:  Calcium (mg) 456±81 673±65* 563±121 625±171 509±82 649±97 
CON:  Calcium (mg) 646±183 515±130 1073±305 482±122 860±170 499±88 
Data are presented as mean ± SEM, with significance set at p<0.05 and signified by “*” as 
compared to baseline measurement within each group.  No between-group comparisons were 
made for this analysis.  Carb=carbohydrate, Phos=phosphorus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
97 
Figure 7.1 
 
 
Figure 7.1:  Recruitment and retention information for study participants.  a n=1: Non-
compliance Total CON n=1; b n=1: Non-compliance, n=1:  Gastrointestinal Distress, 
Total WHEY n=2; c n=1: Non-compliance, n=1: No longer interested, n=1:  Kidney 
transplant, n=1: Transferred clinics.  Non-compliance was defined as consumption of 
study beverage less than 75% of scheduled dialysis sessions. 
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Figure 7.2 
 
 
 
 
Figure 7.2: Performance on shuttle walk test. Patients in WHEY, SOY, and CON had physical 
performance measured at baseline and final testing using a shuttle walk test.  Changes in the time 
walked during the shuttle walk test for each individual are shown on the left, with group 
averages ± SEM on the right.  The “*” indicates a significant time by treatment interaction.  
Performance on the test increased from baseline to final testing in the WHEY group (p< 0.01), 
decreased in CON (p<0.05), and decreased in SOY, although this decrease was not significant 
(p=0.124). 
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Figure 7.3 
Change in Shuttle Walk Time (seconds)
-120 -100 -80 -60 -40 -20 0 20 40 60 80
TI
B
C
 F
in
al
 (m
cg
/d
L)
140
160
180
200
220
240
260
280
CON
WHEY
SOY
r=0.594
p<0.05
 
 
Figure 7.3:  Correlation between Total Iron Binding Capacity (Final) and Change in Shuttle 
Walk Time.  When all three groups were considered together, TIBC measured at final testing 
was positively associated with change in shuttle walk test (r=0.594, p<0.05).  
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Figure 7.4 
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Figure 7.4:  Comparison of protein intake on dialysis and non-dialysis days, by treatment group. 
In the PRO group, protein intake in grams per kilogram body weight was significantly increased 
on dialysis day from baseline to final testing, which contributed to a significant increase in 
average grams protein per kilogram body weight (p<0.05).  There were no differences between 
baseline and final testing for CON on either day or on average.      
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CHAPTER 8 
 
CONCLUSIONS 
 
Chronic kidney disease patients on maintenance hemodialysis therapy suffer from a 
variety of co-morbid conditions that may be mechanistically linked.  The high rates of these 
conditions, including cardiovascular disease, bone disease, and malnutrition, contribute to the 
low reported quality of life in this population.  Results from this study indicate the safety and 
modest benefits of intradialytic exercise and protein supplementation on a variety of co-morbid 
conditions associated with dialysis. 
 Specifically, we found that a four-intradialytic training program:  
• Improved physical performance as measured by shuttle walk test 
• Reduced a marker of oxidative stress 
• Reduced epicardial fat, cardiovascular disease (CVD) risk 
• Improved circulating factors associated with CVD and bone health (alkaline 
phosphatase, ALP) 
We provided evidence to support the effects of intradialytic protein supplementation for: 
• Attenuating acute inflammation (IL-6) associated with dialysis treatment  
• Improving physical performance as measured by shuttle walk test and gait 
speed (specific to whey protein) 
• Improving circulating factors related to CKD co-morbidities (ALP, ferritin, 
total iron binding capacity, phosphorus, potassium) 
In a mouse model of renal insufficiency, we found a benefit of combined exercise and 
soy protein intake on bone health parameters and plasma urea.   
Taken together, these data suggest intradialytic exercise and protein supplementation to be safe 
and effective therapeutic interventions for this critically ill population.  Furthermore, our lab is 
currently investigating the combined effects of protein and exercise during dialysis, as the 
complexity of the disease suggests multiple therapeutic strategies may be necessary to improve 
the health outcomes and quality of life for dialysis patients. 
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ABBREVIATIONS 
 
AAPH   2-Amidinopropane Hydrochloride  
AC   Arterial Compliance 
AI   Augmentation Index 
ALP   Alkaline Phosphatase 
ANOVA  Analysis of Variance  
ApoE -/-  Apolipoprotein E Knockout  
BLEF   Basic Lower Extremity Function Scale 
BMD   Bone Mineral Density 
BMI   Body Mass Index 
BUN   Blood Urea Nitrogen 
BUN_Creat  Blood Urea Nitrogen to Creatinine Ratio  
BV   Bone Volume 
BV/TV  Relative Bone Volume 
Ca x P   Calcium phosphate product 
CAC   Coronary Artery Calcium 
Cas/Ex   Casein Diet, Exercise-Trained 
Cas/Sed  Casein Diet, Sedentary  
CHF   Coronary Heart Failure/Congestive Heart Failure 
CKD   Chronic Kidney Disease  
CKD-MBD  Chronic Kidney Disease Mineral and Bone Disorder  
CON   Control  
COPD   Chronic Obstructive Pulmonary Disorder 
CRP   C-Reactive Protein  
CVD   Cardiovascular Disease 
DPB   Diastolic Blood Pressure  
DXA   Dual X-Ray Absorptiometry  
ELISA   Enzyme-linked Immunosorbet Assay  
EPO   Erythropoetin  
EX    Exercise  
GEE   Generalized Estimating Equation  
GWLAS  Godin Weekly Leisure Activity Score  
HDL   High Density Lipoprotein 
HDL-C  High Density Lipoprotein Cholesterol 
IGF-1   Insulin-like Growth Factor -1  
IL-1β   Interleukin-1 Beta  
IL-6   Interleukin-6  
IMT    Intima-Media Thickness  
iPTH   Intact Parathyroid Hormone  
ISWT   Incremental Shuttle Walk Test 
KDOQI©  Kidney Disease Outcomes Quality Initiative 
LA VI   Left Atrial Volume Index  
LDL   Low Density Lipoprotein 
LVEDD  Left Ventricular End Diastole Dimension 
LVET   Left Ventricular Ejection Time 
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LVH   Left Ventricular Hypertrophy  
LVM   Left Ventricular Mass  
MBP   Milk Basic Protein 
MCOT   Mitral Value Closure to Opening Time 
MFLM  Mineral Free Lean Mass 
MHS   Mental Health Score 
MI   Myocardial Infarction 
MPI   Myocardial Performance Index 
NKF    National Kidney Foundation  
Npna   Normalized Protein Appearance 
OPG   Osteoprotegerin 
PEM   Protein-Energy Malnutrition 
PMN-Elastase PI Polymorphonuclear Elastase-Protease Inhibitor Complex 
PON   Paraoxonase 
PRO   Protein 
PTH   Parathyroid Hormone 
PWTd   Posterior Wall Thickness  
PWV   Pulse Wave Velocity 
QOL   Quality of Life 
RPE   Rating of Perceived Exertion 
RWT   Relative Wall Thickness 
SBP   Systolic Blood Pressure  
SEM   Standard Error of Measurement 
SFA   Saturated Fatty Acid Intake 
SOY   Soy Protein 
Soy/Ex  Soy Diet, Exercise-Trained 
Soy/Sed  Soy Protein Diet, Sedentary 
SWS   Satisfaction with Life Scale 
TBARS  Thiobarbituric Acid Reactive Substances 
TDS   Total Disability Score  
TIBC   Total Iron Binding Capacity  
TNF-α   Tumor Necrosis Factor Alpha  
TransSat  Transferrin Saturation  
TV   Total Volume 
URR   Urea Reduction Ratio  
VC   Vascular Calcification  
VSMC   Vascular Smooth Muscle Cells  
Wb    Whole Body 
WHEY  Whey Protein  
β    Beta Stiffness Index 
Δ    Delta  
μCT    Micro-Computed Tomography 
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